5G Makes the World Safe for Consumerism

There seems to be no questioning the technological imperative. 5G will, when it is fully operative, increase download speeds such that general mobile phone internet activity will be 20 to 100 times faster, thus, for example, greatly enhancing watching Series TV on the go. 5G will also, its promoters claim, fulfill the promise of both Artificial Intelligence and the internet of things: interconnected smart homes, smart cars, and consumers served by smart farms and operated on by smart machines. Likewise, in genetics, the cracking of DNA and RNA codeswhich may enable current COVID-19 stimulators to allow the body to suppress the virus without a dangerous ingestion of COVIDmay eventually lead to promoting a generalized immunity from many diseases.

What could go wrong? Plenty, say 5G critics in France. Likewise, in the realm of genetic algorithms, the German series Biohackers equally sounds the alarm.

In the U.S. and across Asia, in particular, in China and South Korea, the answer to what can go wrong is Nothing. In the U.S. the debate over 5G is only about how fast and efficient the service is. The criticism is that the Verizon-Apple iPhone 12 and the AT&T-Galaxy 5G rollout, even in the large cities, is only partial, four times rather than 20 times faster. China, meanwhile, leads the world in 5G patents and sees the technology as its way to climb out of the stigma of the worlds low-end manufacturer, throwing off the Made in China labeling to be replaced by the Huawei branding of assembled technology, this time Made in Vietnam. In South Korea, the debate is on how soon 6G will arrive.

Europe is behind in the race to 5G, though one of its two telecom companies, Ericsson, has now announced its ready for a rollout. But not so fast. Across the continent questions are being raised about the safety, the consumerist changes, planned obsolescence and inequality the technology will effectuate, and about how 5G is part of the capitalist profit-driven productivist imperative that has so ravaged the planet. In Germany and Britain, angry citizens have pulled down towers. In France, especially with the rise of a progressive Green Party called EELV, the entire ethos of 5G is being questioned.

The opening salvo against the technology was fired by the Green Party Mayor of Grenoble, Eric Piolle, who questioned its supposed benefits. With 5G I can watch porn in HD in my elevator and know if I still have yogurt in the refrigerator is the way he described the new promised land that proponents claim the network will usher in. In return, the Rothschild banker-turned-President Emmanuel Macron, a prime promoter of neoliberal technology as the savior of French society, labeled the Greens Amish who wanted to return to the era of the oil lamp. His fellow right-wing confrres warned of a Green Peril, using the Cold War overlay of Red Peril, and branded those questioning this imperative as Khmer Green, likening them in the digital realm to Cambodias murderous Khmer Rouge.

There is little doubt that the primary reason 5G, the star of the Christmas consumer push, is being so thoroughly trumpeted is the profits it will reap, forecast to account for 668 billion dollars globally in six years and predicted, with the gain in the sale of mobile phones, with an enhanced gaming experience and with more widespread virtual reality headsets, to account for 5 percent of global GDP this year.

Elements of the French left, though, including Franois Ruffin, a legislator and director of the film Merci, Patron, or Thanks, Boss, a kind of French Roger and Me about Frances richest bosses mercilessly closing factories, have suggested that this technological bounty is being asked to fill the void in lives that are increasingly despairing. Ruffin notes also how this techno-totalitarianism, what media critic Evgeny Morozov calls solutionism, will amplify already existing inequalities. The technology may widen the gaps between the increasingly more plugged-in cities with 5G, the periphery around those cities with 4G, and the countrys rural areas with no G, thus in France exacerbating what is termed the territorial fracture and what in the U.S. might be called the Red/Blue dichotomy.

Echoing Morozov, Ruffin points out this kind of thinking leads not to, for example, regulating agribusiness to produce healthier and more eco-friendly food, but to supplying more intelligent forks. In Catholic France 5G is breathlessly talked about, Ruffin says, as the second coming of the Holy Spirit, illuminating our smartphones in the way the first coming descended on the apostles at Pentecost. In the holy light of such a miracle, the telecom industry shakes off the shackles of any sense of being a public good, and instead regulation becomes only about how market competition can be promoted.

France has always been suspicious of consumer miracles which its leading thinkers have often seen as foisted on it by American capitalism in its drive for global hegemony. Witness Godards Two or Three Things I Know About Her and Weekend and the films of Jacques Tati (Playtime, Mr. Hulots Holiday) in their unfolding of a critique of a French society being remade from without.

The debate here is raising important questions that are given short shrift in the rest of the world. Europe is simply being asked to conform and told that if it does not it will be left out of a mainspring of the global economy, with its devices unable to catch up or be plugged into the global flow.

Studies indicate that the digital economy emits 4 percent of greenhouse gas, a number that is predicted to double in five years and which 5 and 6G will accelerate. The Green Party labels 5G an enevore, that is, energy gorging, noting that mobile phone use already accounts for 2 percent of electric use in France.

The introduction of this speedier technology is designed to increase costs, not only of a monthly mobile bill as more data is accessed and downloaded, but also necessitating replacing existing mobile phones with 5G-ready equipment, phones which are now already on the average replaced every 18 months to 2 years. Eventually, the technology with increased pixilation for faster and clearer viewing will be a part of computers and televisions and, like the changeover in television sets from analog to digital, will require a wholescale worldwide replacement.

The ecological question also involves not only the global waste in disposing of the used devices which is estimated to reach 2 million tons, but also in their creation with 70 kilos or 154 pounds of raw materials, including rare metals, necessary for the assembling of one of these super devices. These rare metals, which emit radiation, are strip-mined in the south of China where production is still largely private and loosely regulated. Elsewhere, 80 percent of the cobalt and tantalum needed for assembly comes from the east of the Republic of Congo, a war-torn area where 40,000 children work in the mining zones.

Consumer enhancement, of course, with the tech companies goes hand in hand with consumer surveillance, and 5G increases the drive to a global data center where billions of data packages will be available to publicity and advertising agencies for use in instantaneously molding and soliciting user taste depending on the content of individual cell phones and the store any consumer passes or, more creepily, any impulses they have. By 2025 it is predicted that 75 billion objects will be interconnected, all transmitting user data so that the refrigerator that is telling you to buy more yogurt is also spying on you. The internet highway becomes a spy way.

The implementation of 5G is also wasteful. Huawei is clearly the global leader in cheap and efficient 5G construction. A mobile phone is made up of a complex of 250,000 inventions and patents. In 2020 the Chinese lead the world with 34 cell phone patents, followed by South Korea and Europe with the U.S. a distant fourth. Yet, in labeling the Chinese company a security riskwhen in fact the real threat is that it is a more skillful competitorand forcing its allies to boycott the company as well, installation of 5G will be more costly with companies required to duplicate already established efforts.

Finally, there is the question of safety. There has been no comprehensive government study on the effects of the increased sonic waves on the human body. Private corporate studies, which are not required to be made public, all negate this possibility, while public studies suggest there may be some danger. The U.S. National Toxicology Program found evidence of cancer tumors in rats exposed to high frequencies, and in Italy, the Ramazzini Institute warned there were potential carcinogens in radio frequencies. The French government has commissioned a thoroughgoing study, the results to be reported in Spring 2021. The newspaper of record Le Monde and 70 legislators have asked for a moratorium until the findings are revealed, but Macrons Minister of Finance Bruno Le Maire wants to hasten 5G installation, warning that a delay would contribute to France losing its digital sovereignty.

The corporate sector sees 5G as simply an economic issue with the question being when and how, not why. The Greens and the French left see 5G, in the way it will change French life, perhaps increasing what the French philosopher Gilles Deleuze called societies of control, as a social and ecological issue and a place where the overwhelming drive to more and faster which has so devastated the planet must be questioned. On the continental, national and individual level, to not have 5G means to drop out of the digital flow, with capital arguing, as Theodor Adorno warned in the mid-20th century, that the worst of all conditions is to be left behind. What a bleak future indeed without porn on our elevators and without knowing if we need another yogurt in our refrigerator!

Are you ready for more genetic engineering?

A series which similarly questions how technological prowess is being implemented and controlled, this time in the area of genomes and the human body, is the German show Biohackers. The series is financed by German government and Bavarian Television funds and shot in the same studio as another German series, Dark, both available on Netflix. The simplicity of Biohackers, which begins with a highly dramatic bio attack on a train and then flashes back to explain how the young female student Mia got there and why she is not susceptible to the attack, works in its favor, as opposed to the labored three-era, almost impenetrable flashbacks of Dark.

The action takes place on the Bavarian campus of the University of Freiburg, the German center of all kinds of genetic engineering experimentation. The students at the school, a band of renegades working on their own socially uplifting mutations, are part of a do-it-yourself biology known as the biotechnological social movement or as bio- or wetware hacking, similar to the early rough and tumble cyberpunks of the internet. Mias roommatesbotanist Chen Lu, monied beauty queen Lotta, and nerd seed experimenter Oleform an international group of scientific Scooby Doos who comes to her rescue as she is first taken under the wing of the universitys star biologist Dr. Tanya Lorenz and then threatened by her, as Mia and her friends expose the ruthlessness of their professors experiments to perfect a subject immune to disease.

Mias futon and her rumpled student quarters are contrasted to the corporate-funded Dr. Lorenzs elaborate multi-storied, impeccably furnished and ordered home in the Bavarian forest, complete with a lab in the basement. As with 5G, Dr. Lorenz issues a warning that Germany, which has lost out and is behind in digital mastery, must conquer the realm of biotechnology to compensate.

Dr. Lorenz, though, is revealed to be experimenting on human subjects, leaving a murderous trail behind her and recalling earlier experiments by the Nazis who also claimed to be benefiting humanity. She is Dr. Mengele in a pants suit. This contemporary version of the former ethos features Lorenz, as Mia points out, marking her subjects with a bar code, as the Nazis burnt prison numbers into their subjects flesh.

We are reminded that the Bavarian countryside and its dark forests hatched Hitler in his first coup attempt and that Freiburg University was the place the philosopher Martin Heidegger, in his moment of embracing National Socialism, accepted an appointment as head of the university until his gradual disgust with the movement resulted in his resignation.

Biohackers, renewed for a second season when the conspiracy to hide the experimentation reaches a national level, does not shy away from the subject of chemical and biological warfare. However, instead of the hackneyed usual and usually insane terrorist, the terror here is far better organized and financed not by rogue fanatics but by a corporate-medical ethos which values profit above human life.

Read more:
5G and 'Biohackers': Technology rules! (Is that a good thing?) - People's World

Recommendation and review posted by Bethany Smith

A new study on the CRISPR and Cas Genes market provides a detailed overview of the demands and consumptions of various products/services associated with the growth dynamics of the market. The in-depth market estimation of various opportunities in the segments is expressed in volumes and revenues during the forecast period 2020 to 2026. The insights and analytics on the CRISPR and Cas Genes market span several pages. These are covered in numerous sections, including, drivers and restraints, challenges and opportunities, regional segmentation and opportunity assessment, end-use/application prospects analysis, and competitive landscape assessment.The global revenues in CRISPR and Cas Genes market are projected to garner a CAGR of 21.2% from during 2020 to 2026.

Key stakeholders in the CRISPR and Cas Genes market including industry players, policymakers, and investors in various countries have been continuously realigning their strategies and approaches to implement them in order to tap into new opportunities. Many in recent months have overhauled their strategies to remain agile in the backdrop of worldwide disruptions caused by the COVID-19 pandemic.

Request for Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=4823

The study also offers scrutiny of the changing government policies amid COVID-19 disruptions. Policymakers in developing and developed nations are framing new regulations to meet the continuing macrocosmic shocks by COVID-19 pandemic. The authors of the report have taken into account the impact analysis of the pandemic, and have elaborated on the trends that will be crucial to the upcoming competitive landscape. New entrants, as well as established players who want to emerge as leaders in the post-COVID era, are taking the impact analysis seriously.

The following insights and evaluations are worth knowing for any market participant, helping them in ascertaining the prevailing dynamics and the future trajectories of the CRISPR and Cas Genes market. They are a part of the estimations of the opportunities in various segments.

Some of the insights and market estimations that make this study unique in approach and effective in guiding stakeholders in understanding the growth dynamics. The study provides:

The report offers detailed regional segmentation of the CRISPR and Cas Genes market which includes shares of each key region in the global landscape during the forecast period. The segmentation is done as follows:

The CRISPR and Cas Genes market report offers a critical quantitative and qualitative assessment of the current and future avenues in the following product segments:

The global CRISPR and Cas Genes market report comes with the following end uses:

A detailed assessment of the growth dynamics includes opportunities and growth trends. Some of the questions pertain to these are answered in the study:

Send an Enquiry @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=4823

The report on the CRISPR and Cas Genes market is unique in its approach and insights-gathering initiatives. Some of the aspects that the study highlight are:

Why Choose Fact.MR?

Fact.MR follows a multidisciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

Continue reading here:
Fact.MR Report: What is the impact of Coronavirus on CRISPR and Cas Genes Market Growth? - The Cloud Tribune

Recommendation and review posted by Bethany Smith

TipRanks

Dividend stocks are the Swiss army knives of the stock market.When dividend stocks go up, you make money. When they dont go up you still make money (from the dividend). Heck, even when a dividend stock goes down in price, its not all bad news, because the dividend yield (the absolute dividend amount, divided by the stock price) gets richer the more the stock falls in price.Knowing all this, wouldnt you like to own find great dividend stocks? Of course you would. Raymond James analysts have chimed in and they are recommending two high-yield dividend stocks for investors looking to find protection for their portfolio. These are stocks with a specific set of clear attributes: a dividend yield of 10% and Strong Buy ratings.Kimbell Royalty Partners (KRP)Well start with Kimbell Royalty Partners, a land investment company operating in some of the US major oil and gas producing regions: the Bakken of North Dakota, Pennsylvanias Appalachian region, the Colorado Rockies, and several formations in Texas. Kimbell owns mineral rights in more than 13 million acres across these regions, and collects royalties from over 95,000 active wells. Over 40,000 of those wells are in the Permian Basin of Texas, the famous oil formation that has, in the past decade, helped turn the US from a net importer of hydrocarbons to a net exporter.The coronavirus crisis hit Kimbell directly in the pocketbook, knocking down share prices and earnings as economic restrictions, social lockdowns, and the economic downturn all struck at production and demand. The situation has only begun to revive, with the Q3 revenues growing 44% sequentially to reach $24.3 million.Kimbell has long been a reliable dividend payer, with a twist. Where most dividend stocks keep their payouts stable, typically making just adjustment in a year, Kimbell has a history of reevaluating its dividend payment every quarter. The result is a dividend that is rarely predictable but is always affordable for the company. The last declaration, for the third quarter, was 19 cents per common share, or up 46% from the previous quarter. At that rate, the dividend yields ~10%,Covering the stock for Raymond James, analyst John Freeman noted, Despite a strong quarterly performance and a nearly 50% distribution raise in 3Q, the market continues to under appreciate the unique value proposition of Kimbell's assets, in our view. Kimbell has a best-in-class 13% base decline, exposure to every major basin and commodity, as well as a very manageable leverage profileRegarding the possible anti-hydrocarbon stance of a Biden Administration, Freeman sees little reason for worry, saying, Investors concerned about a potential Biden presidency (which appears increasingly likely) have little to fear in KRP. The company has less than ~2% of acreage on federal lands, meaning a frac ban on those properties would not have a material impact on KRP's business and might actually help them if it improved the overall supply impact."In line with these comments, Freeman rates KRP a Strong Buy, and his $9 price target implies it has room for 25% growth going forward. (To watch Freemans track record, click here)Wall Street appears to agree with Freeman, and the analyst consensus view is also a Strong Buy, based on 5 unanimous positive reviews. This stock is priced at $7.21, and its $11 average target is even more bullish than Freemans, suggesting a one-year upside of ~52%. (See KRP stock analysis on TipRanks)NexPoint Real Estate Finance (NREF)NexPoint inhabits the real estate trust niche, investing in mortgage loans on rental units, both single- and multi-family occupancy, along with self-storage units and office spaces. The company operates in the US, across major metropolitan hubs.NexPoint held its IPO in February this year, just before the coronavirus pandemic inspired an economic crisis. The offering saw 5 million shares sell, and brought in some $95 million in capital. Since then, the shares are down 13%. Earnings, however, have posted gains in each full quarter that the company has reported as a public entity, coming in at 37 cents per share in Q2 and 52 cents in Q3. The Q3 number was 30% above the forecast.The dividend here is also solid. NexPoint started out with a 22-cent per share payment in Q1, and raised it in Q2 to its current level of 40 cents per common share. This annualizes to $1.60, making the yield an impressive ~10%.Stephan Laws, 5-star analyst with Raymond James, is impressed with what he sees here. Laws writes of NexPoint, Recent investments should drive significant core earnings growth, which is reflected in the increased 4Q guidance range of $0.49-0.53 per share (up from $0.46-0.50 per share). The guidance incorporates the full quarter impact of the new 3Q investments as well as new mezz investments made in October. We are increasing our 4Q and 2021 estimates, and we have increased confidence in our forecast for a 1Q21 dividend increase, which we now forecast at $0.45 per shareFollowing these sentiments, Laws puts a Strong Buy rating on NREF. His $18 price target suggest the stock has a 9% upside potential for the year ahead. (To watch Laws track record, click here)With 2 recent Buy reviews, the analyst consensus on NREF shares is a Moderate Buy. The stocks $18 average price target matches Laws, implying 9% growth. (See NREF stock analysis on TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Read the rest here:
CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference - Yahoo Finance

Recommendation and review posted by Bethany Smith

DUBLIN, Nov. 30, 2020 /PRNewswire/ -- The "CRISPR Technology Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

This report describes and evaluates the global CRISPR technology market. It covers 2015 to 2019, termed the historic period, and 2019 to 2023 termed the forecast period, along with further forecasts for the periods 2023-2025 and 2025-2030.

The global CRISPR technology market reached a value of nearly $685.5 million in 2019, having increased at a compound annual growth rate (CAGR) of 35.0% since 2015. The market is expected to grow from $685.5 million in 2019 to $1,654.2 million in 2020 at a rate of 24.6%. It is expected to reach $2,569.8 million in 2023, and $6,703.7 million in 2030.

Growth in the historic period resulted from rise in funding, and increase in pharmaceutical R&D expenditure. Factors that negatively affected growth in the historic period were regulatory challenges, and lack of standardized regulations in the majority of countries.

Going forward, rising demand for gene therapeutics, technological advancements in the fields of genome editing, growing demand for the discovery of drugs, increasing demand for CRISPR in diagnostics, rising demand for CRISPR technologies in agriculture applications, and rising adoption of CRISPR technologies will drive the growth. Factors that could hinder the growth of the CRISPR technology market in the future include ethical concerns related to genetic research, and increasing occurrence of off-target genome editing.

The CRISPR technology market is segmented by product type into Cas9 And gRNA, design tool, plasmid and vector, and other delivery system products. The Cas9 And gRNA market was the largest segment of the CRISPR technology market segmented by product type, accounting for 76.4% of the total in 2019. Going forward, the design tool segment is expected to be the fastest growing segment in the CRISPR technology market, at a CAGR of 29.7% during 2019-2023.

The CRISPR technology market is segmented by end-user into biopharmaceutical companies, agricultural biotechnology companies, academic research organizations, and contract research organizations (CROs). The biopharmaceutical companies market was the largest segment of the CRISPR technology market segmented by end-user, accounting for 55.0% of the total in 2019. Going forward, it is also expected to be the fastest growing segment in the CRISPR technology market segmented by end-user, at a CAGR of 26.0% during 2019-2023.

The CRISPR technology market is segmented by application into biomedical, agriculture, diagnostics, and others. The biomedical market was the largest segment of the CRISPR technology market segmented by application, accounting for 53.0% of the total in 2019. Going forward, it is also expected to be the fastest growing segment in the CRISPR technology market segmented by application, at a CAGR of 25.7%.

North America was the largest region in the global CRISPR technology market, accounting for 51.3% of the total in 2019. It was followed by Asia Pacific, Western Europe, and then the other regions. Going forward, the fastest-growing regions in the CRISPR technology market will be the Middle East, and South America, where growth will be at CAGRs of 130.6% and 41.1% respectively during 2019-2023. These will be followed by Asia Pacific, and Eastern Europe, where the markets are expected to grow at CAGRs of 31.2% and 30.1% respectively during 2019-2023.

The global CRISPR technology market is highly concentrated with few players dominating the market. The top ten competitors in the market made up to 85% of the total market in 2019. Major players in the market include Crispr Therapeutics, Thermo Fisher Scientific, Intellia Therapeutics, Horizon Discovery, and Synthego Corporation.

The top opportunities in the CRISPR technology market segmented by product type will arise in the Cas9 And gRNA segment, which will gain $698.9 million of global annual sales by 2023. The top opportunities in the CRISPR technology market segmented by end-user will arise in the biopharmaceutical companies, which will gain $572.9 million of global annual sales by 2023. The top opportunities in the CRISPR technology market segmented by application will arise in the biomedical, which will gain $542.9 million of global annual sales by 2023. The CRISPR technology market size will gain the most in the USA at $288.4million.

Competitive Landscape

Global CRISPR Technology Market Competitive Landscape

Key Mergers And Acquisitions In The CRISPR Technology Market

Key Topics Covered:

1. CRISPR Technology Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction 6.1.1. Segmentation By Geography 6.1.2. Segmentation By Product Type 6.1.3. Segmentation By End-User 6.1.4. Segmentation By Application

7. CRISPR Technology Market Characteristics 7.1. Market Definition 7.2. Segmentation By Product Type 7.2.1. Cas9 And gRNA 7.2.2. Design Tools 7.2.3. Plasmid And Vector 7.2.4. Other Delivery System Products 7.3. Segmentation By End User 7.3.1. Academic Research Organizations 7.3.2. Biopharmaceutical Companies 7.3.3. Agricultural Biotechnology Companies 7.3.4. Contract Research Organizations (CROs) 7.4. Segmentation By Application 7.4.1. Biomedical 7.4.2. Agriculture 7.4.3. Diagnostics 7.4.4. Others

8. CRISPR Technology Market Trends And Strategies 8.1. Technological Advances 8.2. Increased Demand For CRISPR Technology In Drug Discovery And Screening 8.3. Joint Venture And Strategic Collaboration Between Companies 8.4. Increasing Adoption Of CRISPR Technologies By Agriculture-Based Companies 8.5. Startups In CRISPR Technology 8.6. Artificial Intelligence With CRISPR 8.7. License Agreements Between CRISPR Technology Companies And Biotechnology Firms

9. Impact Of COVID-19 On CRISPR Technology Market 9.1. Impact On CRISPR Technology Companies 9.2. Applications of CRISPR in COVID-19

10. Global CRISPR Technology Market Size And Growth 10.1. Market Size 10.2. Historic Market Growth, 2015 - 2019, Value ($ Million) 10.2.1. Drivers Of The Market 2015 - 2019 10.2.2. Restraints On The Market 2015 - 2019 10.3. Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million) 10.3.1. Drivers Of The Market 2019 - 2023 10.3.2. Restraints On The Market 2019 - 2023

11. Global CRISPR Technology Market Segmentation 11.1. Global CRISPR Technology Market, Segmentation By Product Type, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million) 11.1.1. Cas9 And gRNA 11.1.2. Design Tool 11.1.3. Plasmid And Vector 11.1.4. Other Delivery System Products 11.2. Global CRISPR Technology Market, Segmentation By End-User, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million) 11.2.1. Biopharmaceutical Companies 11.2.2. Agricultural Biotechnology Companies 11.2.3. Academic Research Organizations 11.2.4. Contract Research Organizations (CROs) 11.3. Global CRISPR Technology Market, Segmentation By Application, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million) 11.3.1. Biomedical 11.3.2. Agriculture 11.3.3. Diagnostics 11.3.4. Others

12. CRISPR Technology Market, Regional And Country Analysis 12.1. Global CRISPR Technology Market, By Region, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million) 12.2. Global CRISPR Technology Market, By Country, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)

For more information about this report visit https://www.researchandmarkets.com/r/h5q78p

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more from the original source:
Global $6.7 Billion CRISPR Technology Market Opportunities to 2030: Cas9 And gRNA, Design Tool, Plasmid and Vector, Other Delivery System Products -...

Recommendation and review posted by Bethany Smith

CRISPR Therapeutics AG [NASDAQ: CRSP] jumped around 11.55 points on Friday, while shares priced at $121.55 at the close of the session, up 10.50%. The company report on November 24, 2020 that CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020, at 9:30 a.m. ET.

A live webcast of the event will be available on the Events & Presentations page in the Investors section of the Companys website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Companys website for 14 days following the presentation.

CRISPR Therapeutics AG stock is now 99.57% up from its year-to-date (YTD) trading value. CRSP Stock saw the intraday high of $124.43 and lowest of $110.355 per share. The companys 52-week high price is 111.90, which means current price is +276.32% above from all time high which was touched on 11/27/20.

Compared to the average trading volume of 903.62K shares, CRSP reached a trading volume of 1124305 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRSP shares is $102.63 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRSP stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

RBC Capital Mkts have made an estimate for CRISPR Therapeutics AG shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on October 23, 2020. While these analysts kept the previous recommendation, BofA Securities raised their target price to Buy. The new note on the price target was released on October 05, 2020, representing the official price target for CRISPR Therapeutics AG stock. Previously, the target price had yet another raise from $84 to $105, while Needham kept a Buy rating on CRSP stock.

The Average True Range (ATR) for CRISPR Therapeutics AG is set at 5.67, with the Price to Sales ratio for CRSP stock in the period of the last 12 months amounting to 100.41. The Price to Book ratio for the last quarter was 6.35, with the Price to Cash per share for the same quarter was set at 21.36.

CRISPR Therapeutics AG [CRSP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.27. With this latest performance, CRSP shares gained by 28.34% in over the last four-week period, additionally plugging by 82.53% over the last 6 months not to mention a rise of 78.46% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRSP stock in for the last two-week period is set at 74.92, with the RSI for the last a single of trading hit 82.45, and the three-weeks RSI is set at 68.66 for CRISPR Therapeutics AG [CRSP]. The present Moving Average for the last 50 days of trading for this stock 96.86, while it was recorded at 112.25 for the last single week of trading, and 74.64 for the last 200 days.

Operating Margin for any stock indicates how profitable investing would be, and CRISPR Therapeutics AG [CRSP] shares currently have an operating margin of +16.14. CRISPR Therapeutics AGs Net Margin is presently recorded at +23.09.

Return on Total Capital for CRSP is now 6.75, given the latest momentum, and Return on Invested Capital for the company is 9.72. Return on Equity for this stock inclined to 10.04, with Return on Assets sitting at 8.59. When it comes to the capital structure of this company, CRISPR Therapeutics AG [CRSP] has a Total Debt to Total Equity ratio set at 5.59. Additionally, CRSP Total Debt to Total Capital is recorded at 5.30, with Total Debt to Total Assets ending up at 4.93. Long-Term Debt to Equity for the company is recorded at 4.69, with the Long-Term Debt to Total Capital now at 4.44.

Reflecting on the efficiency of the workforce at the company, CRISPR Therapeutics AG [CRSP] managed to generate an average of $219,928 per employee. Receivables Turnover for the company is 135.10 with a Total Asset Turnover recorded at a value of 0.37.CRISPR Therapeutics AGs liquidity data is similarly interesting compelling, with a Quick Ratio of 16.50 and a Current Ratio set at 16.50.

With the latest financial reports released by the company, CRISPR Therapeutics AG posted 0.51/share EPS, while the average EPS was predicted by analysts to be reported at -0.63/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 181.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CRSP.

There are presently around $5,761 million, or 69.30% of CRSP stock, in the hands of institutional investors. The top three institutional holders of CRSP stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 8,457,320, which is approximately 30.449% of the companys market cap and around 1.30% of the total institutional ownership; CAPITAL INTERNATIONAL INVESTORS, holding 7,394,274 shares of the stock with an approximate value of $898.77 million in CRSP stocks shares; and NIKKO ASSET MANAGEMENT AMERICAS, INC., currently with $449.45 million in CRSP stock with ownership of nearly -0.385% of the companys market capitalization.

Positions in CRISPR Therapeutics AG stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 165 institutional holders increased their position in CRISPR Therapeutics AG [NASDAQ:CRSP] by around 12,811,732 shares. Additionally, 122 investors decreased positions by around 4,673,961 shares, while 56 investors held positions by with 29,914,080 shares. The mentioned changes placed institutional holdings at 47,399,773 shares, according to the latest SEC report filing. CRSP stock had 69 new institutional investments in for a total of 1,942,641 shares, while 36 institutional investors sold positions of 1,051,583 shares during the same period.

See more here:
CRISPR Therapeutics AG [CRSP] Revenue clocked in at $77.40 million, up 99.57% YTD: Whats Next? - The DBT News

Recommendation and review posted by Bethany Smith

Global Crispr And Crispr-Associated (Cas) Genes Market report offers the latest industry trends, technological innovations and forecast market data. In-depth view or analysis of Crispr And Crispr-Associated (Cas) Genes industry based on market size, Crispr And Crispr-Associated (Cas) Genes growth, development plans, and opportunities is offered by this report. The comprehensive market forecast data, SWOT analysis, Crispr And Crispr-Associated (Cas) Genes barriers, and feasibility study are the vital aspects analyzed in this report.

The up-to-date, comprehensive analysis, industry development curve, end clients will drive the income and benefit. Crispr And Crispr-Associated (Cas) Genes report review the present condition with the business to probe/explore the future development openings and risk factors. Crispr And Crispr-Associated (Cas) Genes report goes for giving a 360-degree advertise situation. Initially, the report offers Crispr And Crispr-Associated (Cas) Genes introduction, fundamental overview, objectives, market definition, market size estimation, market scope, concentration and maturity analysis is conducted to understand development opportunities

Download Free Sample Pdf Report @ https://www.globalmarketers.biz/report/life-sciences/global-crispr-and-crispr-associated-(cas)-genes-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/131472#request_sample

List Of Key Players

Caribou BiosciencesAddgeneCRISPR THERAPEUTICSMerck KGaAMirus Bio LLCEditas MedicineTakara Bio USAThermo Fisher ScientificHorizon Discovery GroupIntellia TherapeuticsGE Healthcare Dharmacon

Crispr And Crispr-Associated (Cas) Genes Market Segmentation: By Types

Genome EditingGenetic engineeringgRNA Database/Gene LibrarCRISPR PlasmidHuman Stem CellsGenetically Modified Organisms/CropsCell Line Engineering

Crispr And Crispr-Associated (Cas) Genes Market Segmentation: By Applications

Biotechnology CompaniesPharmaceutical CompaniesAcademic InstitutesResearch and Development Institutes

Ask for Discount @:

https://www.globalmarketers.biz/discount_inquiry/discount/131472

Crispr And Crispr-Associated (Cas) Genes study helps the readers in comprehension the growth factors, industry plans, policies and development strategies implemented by leading Crispr And Crispr-Associated (Cas) Genes players. Every one of the wordings of this market are covered in the report. The report examinations statistical data points to derive the worldwide Crispr And Crispr-Associated (Cas) Genes income. A detailed explanation of Crispr And Crispr-Associated (Cas) Genes market values, potential consumers and the future scope are presented in this report.

Reasons To Buy What was the size of the Global Crispr And Crispr-Associated (Cas) Genes market by value in 2015-2019 and What will be in 2026? What factors are affecting the strength of competition in the Global Crispr And Crispr-Associated (Cas) Genes market? How has the market performed over the last Six years? What are the main segments that make up the global Crispr And Crispr-Associated (Cas) Genes market?

InquiryHere For More Details https://www.globalmarketers.biz/report/life-sciences/global-crispr-and-crispr-associated-(cas)-genes-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/131472#inquiry_before_buying

Some of the Points cover in Global Crispr And Crispr-Associated (Cas) Genes Market Research Report is:Chapter 1: Describe Crispr And Crispr-Associated (Cas) Genes Industry

Chapter 2: To analyze the top manufacturers of Crispr And Crispr-Associated (Cas) Genes Industry in 2017 and 2018

Chapter 3: Competitive analysis among the top manufacturers in 2017 and 2018

Chapter 4: Global Crispr And Crispr-Associated (Cas) Genes Market by regions from 2015 to 2019

Chapter 5, 6, 7 and 8: Global Crispr And Crispr-Associated (Cas) Genes Market by key countries in these regions

Chapter 9 and 10: Global Crispr And Crispr-Associated (Cas) Genes Market by type and application from 2015 to 2019

Chapter 11:Crispr And Crispr-Associated (Cas) Genes Industry Market forecast from 2019 to 2026

Chapter 12 and 13:Crispr And Crispr-Associated (Cas) Genes Industry

Browse Detailed Table Of [emailprotected] https://www.globalmarketers.biz/report/life-sciences/global-crispr-and-crispr-associated-(cas)-genes-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/131472#table_of_contents

Contact Us:

Company Name: Globalmarketers.biz

Contact Person: Alex White

Email: [emailprotected]lmarketers.biz

Phone: +1(617)2752538

Original post:
Crispr And Crispr-Associated (Cas) Genes Market trends, Forecast Analysis, Key segmentation by type and application to 2026 - Cheshire Media

Recommendation and review posted by Bethany Smith

The global CRISPR And CRISPR-Associated (Cas) Genes market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global CRISPR And CRISPR-Associated (Cas) Genes market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global CRISPR And CRISPR-Associated (Cas) Genes market. The authors of the report profile leading companies of the global CRISPR And CRISPR-Associated (Cas) Genes market, such as , Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon They provide details about important activities of leading players in the competitive landscape.

The report predicts the size of the global CRISPR And CRISPR-Associated (Cas) Genes market in terms of value and volume for the forecast period 2019-2026. As per the analysis provided in the report, the global CRISPR And CRISPR-Associated (Cas) Genes market is expected to rise at a CAGR of XX % between 2019 and 2026 to reach a valuation of US$ XX million/billion by the end of 2026. In 2018, the global CRISPR And CRISPR-Associated (Cas) Genes market attained a valuation of US$_ million/billion. The market researchers deeply analyze the global CRISPR And CRISPR-Associated (Cas) Genes industry landscape and the future prospects it is anticipated to create.

This publication includes key segmentations of the global CRISPR And CRISPR-Associated (Cas) Genes market on the basis of product, application, and geography (country/region). Each segment included in the report is studied in relation to different factors such as consumption, market share, value, growth rate, and production.

Get Sample Copy of This Report:https://www.qyresearch.com/sample-form/form/1434599/global-crispr-and-crispr-associated-cas-genes-market

The comparative results provided in the report allow readers to understand the difference between players and how they are competing against each other. The research study gives a detailed view of current and future trends and opportunities of the global CRISPR And CRISPR-Associated (Cas) Genes market. Market dynamics such as drivers and restraints are explained in the most detailed and easiest manner possible with the use of tables and graphs. Interested parties are expected to find important recommendations to improve their business in the global CRISPR And CRISPR-Associated (Cas) Genes market.

Readers can understand the overall profitability margin and sales volume of various products studied in the report. The report also provides the forecasted as well as historical annual growth rate and market share of the products offered in the global CRISPR And CRISPR-Associated (Cas) Genes market. The study on end-use application of products helps to understand the market growth of the products in terms of sales.

Global CRISPR And CRISPR-Associated (Cas) Genes Market by Product: , :, Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering ,

Global CRISPR And CRISPR-Associated (Cas) Genes Market by Application: :, Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research and Development Institutes

The report also focuses on the geographical analysis of the global CRISPR And CRISPR-Associated (Cas) Genes market, where important regions and countries are studied in great detail.

Global CRISPR And CRISPR-Associated (Cas) Genes Market by Geography:

Methodology

Our analysts have created the report with the use of advanced primary and secondary research methodologies.

As part of primary research, they have conducted interviews with important industry leaders and focused on market understanding and competitive analysis by reviewing relevant documents, press releases, annual reports, and key products.

For secondary research, they have taken into account the statistical data from agencies, trade associations, and government websites, internet sources, technical writings, and recent trade information.

Enquire For Customization in the Report:https://www.qyresearch.com/customize-request/form/1434599/global-crispr-and-crispr-associated-cas-genes-market

Key questions answered in the report:

Table Of Contents:

Table of Contents 1 CRISPR And CRISPR-Associated (Cas) Genes Market Overview1.1 Product Overview and Scope of CRISPR And CRISPR-Associated (Cas) Genes1.2 CRISPR And CRISPR-Associated (Cas) Genes Segment by Type1.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Growth Rate Comparison by Type (2021-2026)1.2.2 Genome Editing1.2.3 Genetic engineering1.2.4 gRNA Database/Gene Librar1.2.5 CRISPR Plasmid1.2.6 Human Stem Cells1.2.7 Genetically Modified Organisms/Crops1.2.8 Cell Line Engineering1.3 CRISPR And CRISPR-Associated (Cas) Genes Segment by Application1.3.1 CRISPR And CRISPR-Associated (Cas) Genes Sales Comparison by Application: 2020 VS 20261.3.2 Biotechnology Companies1.3.3 Pharmaceutical Companies1.3.4 Academic Institutes1.3.5 Research and Development Institutes1.4 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Estimates and Forecasts1.4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue 2015-20261.4.2 Global CRISPR And CRISPR-Associated (Cas) Genes Sales 2015-20261.4.3 CRISPR And CRISPR-Associated (Cas) Genes Market Size by Region: 2020 Versus 2026 2 Global CRISPR And CRISPR-Associated (Cas) Genes Market Competition by Manufacturers2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Market Share by Manufacturers (2015-2020)2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Share by Manufacturers (2015-2020)2.3 Global CRISPR And CRISPR-Associated (Cas) Genes Average Price by Manufacturers (2015-2020)2.4 Manufacturers CRISPR And CRISPR-Associated (Cas) Genes Manufacturing Sites, Area Served, Product Type2.5 CRISPR And CRISPR-Associated (Cas) Genes Market Competitive Situation and Trends2.5.1 CRISPR And CRISPR-Associated (Cas) Genes Market Concentration Rate2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)2.6 Manufacturers Mergers & Acquisitions, Expansion Plans2.7 Primary Interviews with Key CRISPR And CRISPR-Associated (Cas) Genes Players (Opinion Leaders) 3 CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario by Region3.1 Global CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario in Sales by Region: 2015-20203.2 Global CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario in Revenue by Region: 2015-20203.3 North America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Country3.3.1 North America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.3.2 North America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.3.3 U.S.3.3.4 Canada3.4 Europe CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Country3.4.1 Europe CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.4.2 Europe CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.4.3 Germany3.4.4 France3.4.5 U.K.3.4.6 Italy3.4.7 Russia3.5 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Region3.5.1 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Sales by Region3.5.2 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Sales by Region3.5.3 China3.5.4 Japan3.5.5 South Korea3.5.6 India3.5.7 Australia3.5.8 Taiwan3.5.9 Indonesia3.5.10 Thailand3.5.11 Malaysia3.5.12 Philippines3.5.13 Vietnam3.6 Latin America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Country3.6.1 Latin America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.6.2 Latin America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.6.3 Mexico3.6.3 Brazil3.6.3 Argentina3.7 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Country3.7.1 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.7.2 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Sales by Country3.7.3 Turkey3.7.4 Saudi Arabia3.7.5 U.A.E 4 Global CRISPR And CRISPR-Associated (Cas) Genes Historic Market Analysis by Type4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Market Share by Type (2015-2020)4.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2015-2020)4.3 Global CRISPR And CRISPR-Associated (Cas) Genes Price Market Share by Type (2015-2020)4.4 Global CRISPR And CRISPR-Associated (Cas) Genes Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global CRISPR And CRISPR-Associated (Cas) Genes Historic Market Analysis by Application5.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Market Share by Application (2015-2020)5.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2015-2020)5.3 Global CRISPR And CRISPR-Associated (Cas) Genes Price by Application (2015-2020) 6 Company Profiles and Key Figures in CRISPR And CRISPR-Associated (Cas) Genes Business6.1 Caribou Biosciences6.1.1 Corporation Information6.1.2 Caribou Biosciences Description, Business Overview and Total Revenue6.1.3 Caribou Biosciences CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.1.4 Caribou Biosciences Products Offered6.1.5 Caribou Biosciences Recent Development6.2 Addgene6.2.1 Addgene CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.2.2 Addgene Description, Business Overview and Total Revenue6.2.3 Addgene CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.2.4 Addgene Products Offered6.2.5 Addgene Recent Development6.3 CRISPR THERAPEUTICS6.3.1 CRISPR THERAPEUTICS CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.3.2 CRISPR THERAPEUTICS Description, Business Overview and Total Revenue6.3.3 CRISPR THERAPEUTICS CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.3.4 CRISPR THERAPEUTICS Products Offered6.3.5 CRISPR THERAPEUTICS Recent Development6.4 Merck KGaA6.4.1 Merck KGaA CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.4.2 Merck KGaA Description, Business Overview and Total Revenue6.4.3 Merck KGaA CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.4.4 Merck KGaA Products Offered6.4.5 Merck KGaA Recent Development6.5 Mirus Bio LLC6.5.1 Mirus Bio LLC CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.5.2 Mirus Bio LLC Description, Business Overview and Total Revenue6.5.3 Mirus Bio LLC CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.5.4 Mirus Bio LLC Products Offered6.5.5 Mirus Bio LLC Recent Development6.6 Editas Medicine6.6.1 Editas Medicine CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.6.2 Editas Medicine Description, Business Overview and Total Revenue6.6.3 Editas Medicine CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.6.4 Editas Medicine Products Offered6.6.5 Editas Medicine Recent Development6.7 Takara Bio USA6.6.1 Takara Bio USA CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.6.2 Takara Bio USA Description, Business Overview and Total Revenue6.6.3 Takara Bio USA CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.4.4 Takara Bio USA Products Offered6.7.5 Takara Bio USA Recent Development6.8 Thermo Fisher Scientific6.8.1 Thermo Fisher Scientific CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.8.2 Thermo Fisher Scientific Description, Business Overview and Total Revenue6.8.3 Thermo Fisher Scientific CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.8.4 Thermo Fisher Scientific Products Offered6.8.5 Thermo Fisher Scientific Recent Development6.9 Horizon Discovery Group6.9.1 Horizon Discovery Group CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.9.2 Horizon Discovery Group Description, Business Overview and Total Revenue6.9.3 Horizon Discovery Group CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.9.4 Horizon Discovery Group Products Offered6.9.5 Horizon Discovery Group Recent Development6.10 Intellia Therapeutics6.10.1 Intellia Therapeutics CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.10.2 Intellia Therapeutics Description, Business Overview and Total Revenue6.10.3 Intellia Therapeutics CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.10.4 Intellia Therapeutics Products Offered6.10.5 Intellia Therapeutics Recent Development6.11 GE Healthcare Dharmacon6.11.1 GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served6.11.2 GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes Description, Business Overview and Total Revenue6.11.3 GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue and Gross Margin (2015-2020)6.11.4 GE Healthcare Dharmacon Products Offered6.11.5 GE Healthcare Dharmacon Recent Development 7 CRISPR And CRISPR-Associated (Cas) Genes Manufacturing Cost Analysis7.1 CRISPR And CRISPR-Associated (Cas) Genes Key Raw Materials Analysis7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price Trend7.1.3 Key Suppliers of Raw Materials7.2 Proportion of Manufacturing Cost Structure7.3 Manufacturing Process Analysis of CRISPR And CRISPR-Associated (Cas) Genes7.4 CRISPR And CRISPR-Associated (Cas) Genes Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers8.1 Marketing Channel8.2 CRISPR And CRISPR-Associated (Cas) Genes Distributors List8.3 CRISPR And CRISPR-Associated (Cas) Genes Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porters Five Forces Analysis 10 Global Market Forecast10.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Estimates and Projections by Type10.1.1 Global Forecasted Sales of CRISPR And CRISPR-Associated (Cas) Genes by Type (2021-2026)10.1.2 Global Forecasted Revenue of CRISPR And CRISPR-Associated (Cas) Genes by Type (2021-2026)10.2 CRISPR And CRISPR-Associated (Cas) Genes Market Estimates and Projections by Application10.2.1 Global Forecasted Sales of CRISPR And CRISPR-Associated (Cas) Genes by Application (2021-2026)10.2.2 Global Forecasted Revenue of CRISPR And CRISPR-Associated (Cas) Genes by Application (2021-2026)10.3 CRISPR And CRISPR-Associated (Cas) Genes Market Estimates and Projections by Region10.3.1 Global Forecasted Sales of CRISPR And CRISPR-Associated (Cas) Genes by Region (2021-2026)10.3.2 Global Forecasted Revenue of CRISPR And CRISPR-Associated (Cas) Genes by Region (2021-2026)10.4 North America CRISPR And CRISPR-Associated (Cas) Genes Estimates and Projections (2021-2026)10.5 Europe CRISPR And CRISPR-Associated (Cas) Genes Estimates and Projections (2021-2026)10.6 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Estimates and Projections (2021-2026)10.7 Latin America CRISPR And CRISPR-Associated (Cas) Genes Estimates and Projections (2021-2026)10.8 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Original post:
CRISPR And CRISPR-Associated (Cas) Genes Market Competitive Insights with Global Outlook 2020-2026| Caribou Biosciences, Addgene, CRISPR THERAPEUTICS...

Recommendation and review posted by Bethany Smith

CRISPR Genome EditingMarket research report provides various levels of analysis such as industry analysis (industry trends), market share analysis of top players, and company profiles, which together provide an overall view on the competitive landscape; emerging and high-growth segments of the CRISPR Genome Editingmarket; high-growth regions; and market drivers, restraints, challenges, and opportunities.

The CRISPR Genome Editingmarket report elaborates insights on the Market Diversification (Exhaustive information about new products, untapped regions, and recent developments), Competitive Assessment (In-depth assessment of market shares, strategies, products, and manufacturing capabilities of leading players in the CRISPR Genome Editingmarket).

Premium Insights on CRISPR Genome Editing Market 2020 with Market Players PositioningRequest For Exclusive Free Sample PDF Copy:https://inforgrowth.com/sample-request/6431512/crispr-genome-editing-market

Market segmentation based on the Key Players, Types & Applications.

CRISPR Genome EditingMarket on the basis of Product Type:Genetic Engineering, Gene Library, Human Stem Cells, Others

CRISPR Genome EditingMarket on the basis of Applications:Biotechnology Companies, Pharmaceutical Companies, Others

Top Key Players in CRISPR Genome Editingmarket: Editas Medicine, CRISPR Therapeutics, Horizon Discovery, Sigma-Aldrich, Genscript, Sangamo Biosciences, Lonza Group, Integrated DNA Technologies, New England Biolabs, Origene Technologies, Transposagen Biopharmaceuticals, Thermo Fisher Scientific, Caribou Biosciences, Precision Biosciences, Cellectis, Intellia Therapeutics

Get up to 30% instant discount Under Our Thanksgiving Discount OFFER;https://inforgrowth.com/discount/6431512/crispr-genome-editing-market

This report brings together multiple data sources to provide a comprehensive overview of CRISPR Genome Editing.

It includes analysis on the following

Make Inquiry for More Insights:https://inforgrowth.com/enquiry/6431512/crispr-genome-editing-market

Reasons to Buy CRISPR Genome Editingmarket Report:

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898

Link:
CRISPR Genome Editing Market Statistics and Research Analysis Released in Latest Industry Report 2020 | Coronavirus-COVID19 Impact Analysis With Top...

Recommendation and review posted by Bethany Smith

The research report of CRISPR Genome Editing Market study report covers all main geographical regions and sub-regions in the world and focuses on product sales, cost, and CRISPR Genome Editing market size and growth opportunities in these regions. The CRISPR Genome Editing market industry provides market research data status categorizes the CRISPR Genome Editing market into key dynamics, region, type and application.

The analysis of CRISPR Genome Editing market offers a competitive head-start to businesses operating in this vertical through a holistic assessment of the growth matrix and global developments. The report throws light on the opportunities, limitations, and crucial growth drivers that determine the profitability of the overall market along with solutions to overcome potential challenges.

Furthermore, the document derives the projected growth rate of the industry from a comparative study over the analysis period. It also provides a comprehensive assessment of the footprint of the COVID-19 pandemic on the market and sub-markets and assists the industry partakers in dealing with the challenges.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/369423

Key Highlights of the Table of Contents:

Product spectrum

Application arena

Regional analysis

Competitive landscape

To conclude, the report has meticulously assessed the CRISPR Genome Editing market through multiple segments, with a deep-dive investigation of facets including the sales channel & supply chain along with specifications pertaining to upstream suppliers, downstream buyers, raw materials, and distributors.

The report can answer the following questions:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/369423

Read this article:
CRISPR Genome Editing Market to Exhibit Impressive Growth of CAGR during the pe - News by aeresearch

Recommendation and review posted by Bethany Smith

Single-cell search: Researchers mutated autism-linked genes in developing mouse embryos using a viral technique. They analyzed the cells carrying mutations (pink) when the mice were 7 days old.

Courtesy of Xin Jin / Harvard

Mutations in a set of 35 genes linked to autism affect both neurons and glial cells in developing mice, according to a study published today. The study is the first to screen multiple autism-gene mutations, one by one, in living mice and analyze their effects in individual brain cells.

About 100 genes have been strongly linked to autism, and sequencing efforts continue to uncover more. But how mutations in each of these genes affect brain development remains largely unknown. Although researchers have investigated the molecular effects of just a few genes, testing all of them individually is a daunting task.

In the new work, researchers built on a technique called Perturb-seq, developed in 2016. This technique mutates the genome in individual cells using CRISPR technology and then sequences the RNA in each cell to determine how the mutation changed it.

Perturb-seq has been used in cells grown in a dish, says Paola Arlotta, professor of stem cell and regenerative biology at Harvard University, who co-led the work, but this is the first time that it is applied in an intact, living and developing organism.

Arlotta and her colleagues injected viruses carrying CRISPR gene-editing machinery into 12-day-old mouse embryos. They used just enough virus to cause mutations in 1 out of every 1,000 stem cells in the embryonic brain.

When the pups were 7 days old, the researchers sequenced the RNA in five different cell types in the pups brains: three types of neurons and two types of glial cells. They then identified groups of mutations in which gene expression had changed in similar ways.

Mutations in several of the autism-linked genes affect common sets of related genes and multiple cell types, they found.

The approach allows researchers to study how different autism-linked genes might converge on similar developmental pathways, says Xin Jin, a junior fellow at Harvard who worked on the study.

The researchers plan to expand the number of genes that the technique can mutate at once, Arlotta says. They also plan to apply it to lab-grown human brain cells that form clusters called organoids, to test whether genes affect development comparably in mice and people.

See the rest here:
Autism genes affect development of neurons and glia - Spectrum

Recommendation and review posted by Bethany Smith

Hopes for new treatments for osteoporosis and cartilage degeneration have been raised after scientists identified a gene that plays a key role in the ageing of bone, tendon, ligament and cartilage.

The researchers hope that they can use their findings to slow down treat age-related diseases connected to the skeletal system by creating treatments that slow down the ageing process behind them.

The i newsletter latest news and analysis

Our findings are novel and significant in finding a critical answer to how skeletal tissues lose their capability to maintain their properties and functions when we age, said Wan-Ju Li, of the University of Wisconsin-Madison.

We can also develop new pharmacological therapies to treat age-associated diseases based on our findings [although] it will take a few years before we can see the application happens, he said.

The study is published in the journal Stem Cells. The journals editor-in-chief, Jan Nolta, of the University of California at Davis, said the discovery is a very important accomplishment.

Researchers said it is possible that the same mechanism that has been identified for the skeletal system may also be present in neural stem cells and cardic stem cells, where it may play a role in causing diseases associated with those areas of the body.

We dont know if the molecule and mechanism we have identified in the paper also play the same role in other stem cells, such as neural stem cells and cardiac stem cells, in causing Parkinsons disease and heart diseases, respectively, since we havent tested it with these cells, Dr Lin said.

But I am sure that other scientists in the fields of aging and brain and heart will follow our study to answer these questions in the future, Dr Lin said.

Follow this link:
Osteoporosis treatments could be on the way after scientists identify aging gene - iNews

Recommendation and review posted by Bethany Smith

Myocardial Infarction Drug used to treat Heart Attack. Medicines and chemical substances that can cause myocardial infarction. Treatment ranges from lifestyle changes and cardiac rehabilitation to medication, stents, and bypass surgery.

Myocardial Infarction Drug Market is anticipated to grow at a CAGR of +6% during the forecast period 2020-2028.

A Global Myocardial Infarction Drug Market analysis and forecast is released based on a wide study of the market. Statistics about the approaching market trends as well as the current scenario of the market is a vital implement for existence and development in the constantly developing industry.

Request a Sample Report.

https://www.reportconsultant.com/request_sample.php?id=77992

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Myocardial Infarction Drug Market which would mention How the Covid-19 is affecting the Myocardial Infarction Drug Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Myocardial Infarction Drug Players to Combat Covid-19 Impact.

The Top Key Players of the global Myocardial Infarction Drug Market:

BioCardia, Inc., Laboratoires Pierre Fabre SA, Human Stem Cells Institute, CSL Limited, Capricor Therapeutics, Inc., Hemostemix Ltd, Compugen Ltd., Celyad SA, FibroGen, Inc., Lees Pharmaceutical Holdings Limited, Juventas Therapeutics, Inc., Cynata Therapeutics Limited, CellProthera, Biscayne Pharmaceuticals, Inc., HUYA Bioscience International, LLC, LegoChem Biosciences, Inc, Immune Pharmaceuticals Inc.

Segmentation by Product type:

Segmentation by Application:

Market Segmentation by Region:

Ask for a Discount on this Report:

https://www.reportconsultant.com/ask_for_discount.php?id=77992

The Global Myocardial Infarction Drug Market has demonstrated an increasing need to alter the policies that are being currently used by the players so as to exhibit commercial capacities of the manufacturers, distributors, and vendors. This helps the key players in developing a firm strategy that is flexible enough to keep up with future events in the market space.

Table of Contents:

About Us:

Report Consultant A global leader in analytics, research, and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly. We make sense of drawbacks, opportunities, circumstances, estimations, and information using our experienced skills and verified methodologies.

Our research reports will give you an exceptional experience with innovative solutions and outcomes. We have effectively steered businesses all over the world with our market research reports and are outstandingly positioned to lead digital transformations. Thus, we craft greater value for clients by presenting advanced opportunities in the global market.

Contact us:

Report Consultant

sales@reportconsultant.com

http://www.reportconsultant.com

Read more here:
Global Myocardial Infarction Drug Market to have sustainable growth over the forecast period 2020-2028| Leading Players BioCardia, Inc., Laboratoires...

Recommendation and review posted by Bethany Smith

This article was originally published here

J Vasc Interv Radiol. 2020 Nov 25:S1051-0443(20)30769-7. doi: 10.1016/j.jvir.2020.09.003. Online ahead of print.

ABSTRACT

PURPOSE: To evaluate safety and efficacy of angiogenesis induced by intraarterial autologous bone marrow-derived stem cell (BMSC) injection in patients with severe peripheral arterial disease (PAD).

MATERIALS AND METHODS: Eighty-one patients with severe PAD (77 men), including 56 with critical limb ischemia (CLI) and 25 with severe claudication, were randomized to receive sham injection (group A) or intraarterial BMSC injection at the site of occlusion (group B). Primary endpoints included improvement in ankle-brachial index (ABI) of > 0.1 and transcutaneous pressure of oxygen (TcPO2) of > 15% at mid- and lower foot at 6 mo. Secondary endpoints included relief from rest pain, > 30% reduction in ulcer size, and reduction in major amputation in patients with CLI and > 50% improvement in pain-free walking distance in patients with severe claudication.

RESULTS: Technical success was achieved in all patients, without complications. At 6 mo, group B showed more improvements in ABI of > 0.1 (35 of 41 [85.37%] vs 13 of 40 [32.50%]; P < .0001) and TcPO2 of > 15% at the midfoot (35 of 41 [85.37%] vs 17 of 40 [42.50%]; P = .0001] and lower foot (37 of 41 [90.24%] vs 19 of 40 [47.50%]; P < .0001). No patients with CLI underwent major amputation in group B, compared with 4 in group A (P = .0390). No significant difference was observed in relief from rest pain or > 30% reduction in ulcer size among patients with CLI or in > 50% improvement in pain-free walking distance among patients with severe claudication.

CONCLUSIONS: Intraarterial delivery of autologous BMSCs is safe and effective in the management of severe PAD.

PMID:33248918 | DOI:10.1016/j.jvir.2020.09.003

Original post:
Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Therapeutic Efficacy of Angiogenesis Induced by Intraarterial Autologous...

Recommendation and review posted by Bethany Smith

There are 206 bones in the human body ranging in size from the tiniest, found in your ear, to the largest, in your thigh.

We have just one heart roughly the size of your fist in our chest and continuously pumping about eight pints of blood.

206 bones and only one heart. But how are the two connected? Does the quality of your bones affect your heart?

BHF-funded researcher Dr Zahra Raisi-Estabragh and her team at Queen Mary University of London recently discovered that poor bone quality is in fact linked to poor heart health.

In this study, they used the UK Biobank the world's largest biomedical database to study the link between osteoporosis and cardiovascular health. Osteoporosis affects over 3 million people in the UK and results in brittle and weak bones that are more likely to break.

We know that osteoporosis and heart disease share a number of risk factors such as increasing age, a sedentary lifestyle, and smoking but are these risk factors all they share? Is there something we havent uncovered yet? This is what Dr Raisi-Estabragh and the team of researchers set out to find.

They discovered that lower bone density (the amount of bone mineral in bone tissue) is linked to stiffer arteries (a sign of poor heart health). They also found that people with poor bone quality have a higher risk of dying from coronary heart disease when the arteries supplying the heart with blood get clogged up with fatty deposits.

With this wealth of information available, the next step will be to identify more of the factors that leave people at high risk of each disease and inform public health policy aimed at improving both bone and heart health.

At the University of Manchester, BHF-funded researcher Dr John Bowes is looking at why coronary heart disease is more common in people with rheumatoid arthritis. Rheumatoid arthritis is an autoimmune disease when your immune system (which usually fights infection) attacks the cells that line your joints by mistake, making the joints swollen, stiff and painful. Over time, this can damage the joints, cartilage and nearby bone.

We know that coronary heart disease causes around half of the early deaths of people with rheumatoid arthritis. Unfortunately, however, there is no effective method to measure the risk of heart disease in people with arthritis, because the risk factors are different in these people. In fact, screening tools based on the usual risk factors (such as high blood pressure, high cholesterol, smoking) are not reliable in predicting the risk of heart disease in people with arthritis.

In comes Dr John Bowes and his team their aim is to create a tool that does just that. First, they will use genetic data and statistical analyses to understand why these two diseases frequently occur together. Based on these results, an accurate tool to identify which people with rheumatoid arthritis are most at risk of coronary heart disease could then be developed.

Your heart is a remarkable organ. It beats about 60 to 100 times every minute, pumping blood and oxygen all around your body with each heartbeat. But theres more to it than that. Your heart also produces a small number of hormones chemical messengers released into the blood and carried to target organs.

BHF-funded researcher Professor Svetlana Reilly and her team at the University of Oxford have recently discovered a new heart hormone calcitonin previously thought to only be produced by the thyroid gland. Published in Nature, the research revealed that cells in the atria (the top chambers of the heart) produce more calcitonin than cells in the thyroid.

It has long been known that calcitonins role in our bodies is to help regulate bone density. However, the Oxford researchers found that calcitonin also plays an important role in reducing atrial scarring. Scarring disrupts the electrical impulses travelling through the atria, which in turn causes the heart to beat in an irregular manner this is known as atrial fibrillation(AF). People with AF may experience dizziness, palpitations, shortness of breath, and tiredness. They are also more at risk of having a stroke.

Around 1.4 million people in the UK have been diagnosed with AF. For most people, this is a shock and emotionally challenging but new research brings new hope. Professor Reilly and her team are making great strides in this area and are hopeful that this bone and heart hormone could lead to new therapies to control or prevent this potentially devastating condition.

Another extraordinary part of the human body is bone marrow the spongy tissue deep inside some of your bones, such as your hip and thigh bones. Bone marrow is essential in repairing tissue damage because it contains stem cells, which can turn into any type of cell in the body, including blood cells.

At the University of Bristol, BHF-funded researcher Professor Paolo Madeddu is studying how diabetescauses damage to bone marrow. We know that diabetes can gradually damage blood vessels, which increases the risk of heart and circulatory diseases. This blood vessel damage impairs blood flow to bone marrow, which in turn decreases the amount of stem cells produced by bone marrow and with it the bodys ability to repair itself.

Using powerful microscopes and scanning machines, the researchers are now investigating the blood circulatory system of bone marrow in around 150 people with diabetes. They hope to find new ways to protect cells in the bone marrow from the damage caused by diabetes.

Maintaining healthy blood vessels and normal bone marrow function is important for people with diabetes, as this could help prevent heart and circulatory diseases in these people diseases which still kill one in four in the UK, and still cause heartbreak in every family.

Help us power our life saving research

We can all agree that 2020 has been a year like no other, but the fact that there are researchers out there using a Nobel Prize-winning discovery to help us beat heartbreak forever to help us live in a world free from the fear of heart and circulatory diseases is exactly what we all needed to know right now.

Read more BHF research blogs

Original post:
How are bones and the heart connected? - British Heart Foundation

Recommendation and review posted by Bethany Smith

MELBOURNE, Australia and BAAR, Switzerland, Nov. 29, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces it has entered into an agreement with Scintec Diagnostics GmbH (Scintec) to acquire TheraPharm GmbH (TheraPharm), a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of hematology.

The acquisition of TheraPharm provides Telix with access to a portfolio of patents, technologies, production systems, clinical data and know-how in relation to the use of Molecularly Targeted Radiation (MTR) in hematology and immunology. TheraPharm is developing antibody MTR technology against CD66, a cell surface target highly expressed by neutrophils (a type of white blood cell) and tumor-infiltrating lymphocytes. As such, the technology has potentially very broad applications in the diagnosis and treatment of hematologic diseases (e.g. blood cancers), lymphoproliferative disorders and immune-mediated diseases (e.g. lupus, and multiple sclerosis). Of particular interest is the demonstrated use of the technology to safely and effectively perform bone marrow conditioning (BMC) prior to bone marrow stem cell transplant.

Telix CEO, Dr. Christian Behrenbruch stated, Telix is committed to extending and improving the lives of patients with serious diseases. As such, the acquisition of TheraPharm and its MTR assets are uniquely aligned to Telixs mission and technical strengths in antibody engineering and radiochemistry. TheraPharms technology has a significant role to play in BMC and stem cell transplantation across a broad range of blood cancers and rare diseases. The current approach to BMC employs highly toxic drugs that have a poor morbidity and mortality profile, and for which many patients are ineligible. MTR offers an excellent safety profile that may greatly expand the number of patients able to undergo life prolonging stem cell transplantation while greatly reducing the hospitalisation burden and cost associated with such procedures.

TheraPharm co-founder and Managing Director, Dr. Klaus Bosslet added, Over the past 5 years, TheraPharm, in collaboration with Dr. Kim Orchard from the University of Southampton (UK), has made excellent progress developing 90Y-besilesomab for the treatment of hematologic cancers and several related conditions including multiple myeloma, leukemia and amyloidosis. This unique asset is a logical addition to Telixs portfolio, offering a potentially rapid development path to a first commercial indication for the treatment of patients with SALA, while at the same time having potentially broad applications for stem cell transplantation in patients with more common cancers of the blood, including multiple myeloma and leukemia. We look forward to joining the Telix team in order to expedite the development of products for this under-served field.

Full transaction details, including financial terms, can be found via the Telix website and ASX portal here.

About Hematopoietic Stem Cell Transplant (HSCT)

Bone marrow conditioning (BMC) followed by hematopoietic stem cell transplantation (HSCT) is presently performed to treat patients with hematologic malignancies (blood cancers), with the objective of extending patient survival or achieving cure. HSCT is also performed for a broad range of non-cancer conditions. HSCT is preferentially performed in countries of high income (Europe >30,000, Americas >20,000, worldwide >65,000 p.a., respectively) and is growing at around 5% annually.

About Systemic Amyloid Light-Chain Amyloidosis (SALA)

SALA is a rare, but serious protein deposition disease, caused by a protein known as amyloid that is produced by abnormal plasma cells residing in the bone marrow. As amyloid accumulates in the organs of the body, organ function will eventually deteriorate, ultimately causing organ failure. SALA has an estimated prevalence of 30,000 and 45,000 in United States and Europe, respectively and while a rare disease, SALA portends a very poor prognosis, with a median survival from diagnosis of ~11 months if untreated.

The current standard of care comprises of induction therapy (typically cyclophosphamide, bortezomib, dexamethasone) plus high dose melphalan BMC, followed by HSCT. This approach is typically only accessible to a small proportion of patients (<20%) who are able to tolerate induction therapy and melphalan BMC.

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit http://www.telixpharma.com.

AboutTheraPharm GmbH

TheraPharm is a biotechnology company specialised in the research, development and manufacturing of monoclonal antibodies for targeted radiation of hematopoietic malignant and non-malignant diseases, lymphoproliferative diseases, conditioning for allogeneic stem cells as well as in diagnostics of inflammatory diseases and bone marrow metastases.

See the article here:
Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine - BioSpace

Recommendation and review posted by Bethany Smith

Report covers a detailed analysis of the Hematopoietic Stem Cell Transplantation (HSCT) Market in the estimated forecast period. It analyses and determines the effect of the external factors which are impacting the revenues and the growth of the market in the estimated forecast period. In addition, with the emergence of the global pandemic, the effect of COVID-19 is also analyzed in the report. Based on the type and applications, introduction of new products and research involved in the development of new products is one of the major aspects which is likely to have an impact on the Hematopoietic Stem Cell Transplantation (HSCT) Market. Similarly, the impact of the COVID-19 on the manufacturing and the effect of the demand for these products is also one of the major aspects which are likely to have an impact on the growth of the market in the estimated forecasts period.

Pandemic offer for our customers: Purchase this Report now by availing up to 30% Discount and free consultation. Limited period offer.

Get Sample Copy of This Report @ https://www.apexmarketreports.com/Life-Science/global-hematopoietic-stem-cell-transplantation-hsctmarket-by-364631#sample

The comprehensive list ofKey Market Playersalong with their market overview, product protocol, key highlights, key financial issues, SWOT analysis, and business strategies:Regen Biopharma IncChina Cord Blood CorpCBR Systems IncEscape Therapeutics IncCryo-Save AGLonza Group LtdPluristem Therapeutics IncViaCord Inc

The following points are involved along with an in-depth study of each point for Hematopoietic Stem Cell Transplantation (HSCT) Market:

Manufacture Analysis Manufacture of the Hematopoietic Stem Cell Transplantation (HSCT) is analyzed with respect to different applications, types and regions.

Resource and Consumption In extension with sales, this segment studies Resource and consumption for the Hematopoietic Stem Cell Transplantation (HSCT) Market. Import export data is also provided by region if applicable.

Additionally, we provide customized report as per our clients requirement.

Historical year: 2015-2019Base year: 2019Forecast period: 2020-2027

Focus on segments and sub-section of the Market are illuminated below:

Geographical Analysis: United States, Europe, China, Japan, Southeast Asia & India, Rest of World etc.

Type Analysis:AllogeneicAutologous

Application Analysis:Peripheral Blood Stem Cells Transplant (PBSCT)Bone Marrow Transplant (BMT)Cord Blood Transplant (CBT)

Each and every segment has been detailed in the report with its market share, revenue, basic data, and highest growing segment globally.

Enquire Before Purchasing This Report at: https://www.apexmarketreports.com/Life-Science/global-hematopoietic-stem-cell-transplantation-hsctmarket-by-364631#inquiry

Global Hematopoietic Stem Cell Transplantation (HSCT) Competitive Analysis:

The key players are aiming innovation to increase efficiency and product life. The long-term growth opportunities available in the sector are captured by ensuring constant process improvements and economic flexibility to spend in the optimal schemes. Company profile section of top players includes its basic information like company legal name, website, headquarters, subsidiaries, its market position, history and 5 closest competitors by Market capitalization / revenue along with contact information.

Industrial Dynamics:

Hematopoietic Stem Cell Transplantation (HSCT) Market Report concentrates on market dynamics which give holistically view on driving factors mainly impacting on growth of Hematopoietic Stem Cell Transplantation (HSCT) market. It also includes restraints that have negative impact along with lucrative opportunities in near future so that readers get an idea about the profitability of market. It also gives complete information about the market scenario due to attack of corona virus. Thus, it also provides threats to the market.

This report is very useful for the new entrants as it offers them with the idea about the different approaches towards the market and the impact of COVID-19.

Continue reading here:
Global Hematopoietic Stem Cell Transplantation (HSCT) Market 2020 Impact of COVID-19, Future Growth Analysis and Challenges | Regen Biopharma Inc,...

Recommendation and review posted by Bethany Smith

(TNS) - Scientists at Bay Area universities, laboratories, biotechnology companies and drug manufacturers are fashioning drug concoctions out of blood plasma, chimpanzee viruses and cells taken from bone marrow in the race to rid the world of COVID-19.

The microbial treasure hunt is not just to find a cure which may not be possible but to control the debilitating health problems caused by the coronavirus.

Major progress has been made this year. The antiviral drug remdesivir, produced in Foster City, has improved recovery times, and the steroid dexamethasone has cut the number of deaths in severely ill patients.

What follows is a list of some of the most promising medications and vaccines with ties to the Bay Area:

Antibodies

and Immunity

Mesenchymal stem cells / UCSF and UC Davis Medical Center:

UCSF Dr. Michael Matthay is leading a study of whether a kind of stem cell found in bone marrow can help critically ill patients with severe respiratory failure, known as ARDS. Matthay hopes the stem cells can help reduce the inflammation associated with some of ARDS' most dire respiratory symptoms, and help patients' lungs recover.

In all, 120 patients are being enrolled at UCSF Medical Center, Zuckerberg San Francisco General Hospital, the UC Davis Medical Center in Sacramento and hospitals in Oregon and Texas. He said the trial, which includes a small number of ARDS patients who don't have COVID-19, should have results by summer or fall 2021. So far, 28 patients are enrolled in San Francisco.

Lambda-interferon / Stanford University:

Lambda-interferon is a manufactured version of a naturally occurring protein that had been used to treat hepatitis, and researchers hoped it would help patients in the early stages of COVID-19.

Stanford researchers completed their trial of lambda-interferon and found that it did not boost the immune system response to coronavirus infections.

"That trial did not find any difference in outcomes between the treatment and placebo," said Yvonne Maldonado, chief of pediatric infectious diseases at Lucile Packard Children's Hospital at Stanford, where 120 patients were enrolled in the trial. "It didn't work."

Antiviral drugs

Remdesivir / Gilead Sciences ( Foster City):

Remdesivir, once conceived as a potential treatment for Ebola, was approved by the Food and Drug Administration in October for use on hospitalized COVID-19 patients.

Trademarked under the name Veklury, the drug interferes with the process through which the virus replicates itself. It was one of the drugs given to President Trump and has been used regularly in hospitals under what is known as an emergency use authorization.

It was approved after three clinical trials showed hospitalized coronavirus patients who received remdesivir recovered five days faster on average than those who received a placebo. Patients who required oxygen recovered seven days faster, according to the studies.

Gilead now plans to conduct clinical trials to see how remdesivir works on pediatric patients, from newborns to teenagers, with moderate to severe COVID-19 symptoms. Remdesivir is also being studied with steroids and other drugs to see if it works better as part of a medicinal cocktail. An inhalable form of the drug is also being developed.

Favipiravir / Fujifilm Toyama Chemical ( Stanford University):

This antiviral drug, developed in 2014 by a subsidiary of the Japanese film company to treat influenza, is undergoing numerous clinical studies worldwide, including a trial involving 180 patients at Stanford University.

Stanford epidemiologists are testing favipiravir to see if it prevents the coronavirus from replicating in human cells, halts the shedding of the virus and reduces the severity of infection. Unlike remdesivir, it can be administered orally, so it can be used to treat patients early in the disease, before hospitalization is necessary.

The Stanford study has so far enrolled about 90 patients, who are given the drug within 72 hours of when they were first diagnosed with COVID-19. Half of them get a placebo. People can enroll by emailing treatcovid@stanford.edu.

Monoclonal antibodies

REGN-COV2 / Regeneron Pharmaceuticals / Stanford School of Medicine:

The REGN-COV2 cocktail is the same one Trump received, and Stanford is one of dozens of locations nationwide where clinical trials are being held. Two separate trials are under way at Stanford one for hospitalized patients, the other for outpatients. A third trial is about to begin for people who aren't sick but are in contact with carriers of the virus.

Regeneron halted testing on severely ill patients requiring high-flow oxygen or mechanical ventilation after the independent Data and Safety Monitoring Board determined that the drug was unlikely to help them.

The drug is a combination of two monoclonal antibodies lab-made clones of the antibodies produced naturally in people who have recovered from COVID-19. The antibodies bind to the virus' spike protein and block the virus' ability to enter cells.

Dr. Aruna Subramanian, professor of infectious diseases at Stanford and lead investigator for the inpatient trial, said the 21 hospitalized patients in the study receive a high dose like Trump, a lower dose or a placebo. Subramanian plans to expand the inpatient trial to 45 patients. The outpatient study has enrolled a little more than 40 of the 60 patients researchers intend to sign up.

"There's enough promising evidence that it helps people early in the infection," Subramanian said. "What we don't know is whether it helps people who are pretty sick but not critically ill."

Bamlanivimab / Eli Lilly / Stanford and UCSF:

Stanford and UCSF are testing the Eli Lilly monoclonal antibodies on outpatients after the pharmaceutical company halted trials on hospitalized COVID-19 patients because of adverse results.

Dr. Andra Blomkalns, chair of emergency medicine at Stanford and the lead in the Eli Lilly outpatient trial, said she is now enrolling older people with comorbidities like heart disease, chronic lung disease, a history of strokes and severe obesity shortly after they test positive.

The hypothesis is that the bamlanivimab monotherapy, which is very similar to the Regeneron monoclonals, might work best early in the infection. Although about 400 patients have been enrolled in the Lilly phase 3 trials nationwide, to date fewer than 10 have been enrolled at Stanford and UCSF.

Matthay, who headed up the Lilly monoclonal study with LY-CoV555 at UCSF, said the cancellation of this inpatient trial was disappointing, but "just because this one did not work, doesn't mean another one won't work for hospitalized patients."

Blomkalns said the testing criteria has been changing. She expects the outpatient trial to open soon to adolescents ages 12 and up to determine whether the drug can be used as a preventive.

Designer monoclonal antibodies / Vir Biotechnology, San Francisco:

Scientists at Vir are studying several types of monoclonal antibodies, including a type engineered to activate T cells, which can search out and destroy cells infected with the coronavirus. A study published in the journal Nature in October found that monoclonals, modified to bind with certain receptors, stimulated T cells and improved the human immune response.

"By observing and learning from our body's powerful natural defenses, we have discovered how to maximize the capacity of antibodies through the amplification of key characteristics that may enable more effective treatments for viral diseases," said Herbert Virgin, the chief scientific officer at Vir and co-author of the study.

A similarly modified monoclonal antibody, leronlimab, is being studied in coronavirus clinical trials by its Washington state drugmaker, CytoDyn, which has developed drugs to treat HIV. The company's chief medical officer is in San Francisco, and the company that does laboratory tests of leronlimab is in San Carlos.

Anti-inflammatory drugs

Colchicine / UCSF ( San Francisco and New York):

The anti-inflammatory drug commonly used to treat gout flare-ups is being studied by scientists at UCSF and New York University. The drug short-circuits inflammation by decreasing the body's production of certain proteins, and researchers hope that it will reduce lung complications and prevent deaths from COVID-19.

Preliminary results from a clinical trial found that "Colchicine can be effective in reducing systemic symptoms of COVID-19 by inhibiting inflammatory biomarkers."

Selinexor / Kaiser Permanente:

Kaiser hospitals in San Francisco, Oakland and Sacramento are studying selinexor, an anticancer drug that blocks a key protein in the cellular machinery for DNA processing. Preliminary findings during the trials indicated that low doses of selinexor helped hospitalized patients with severe COVID-19. The drug has both antiviral and anti-inflammatory properties, and it's administered orally, according to Kaiser's Dr. Jacek Skarbinski.

Vaccines

VXA-COV2-1 / Vaxart, South San Francisco:

The biotechnology company Vaxart is testing VXA-COV2-1, the only potential vaccine in pill form. It uses the genetic code of the coronavirus to trigger a defensive response in mucous membranes. The hope is that the newly fortified membranes will prevent the virus from entering the body.

"It's the only vaccine (candidate) that activates the first line of defense, which is the mucosa," said Andrei Floroiu, Vaxart's chief executive. He said intravenous vaccines kill the virus after it is inside the body, but this one stops it beforehand.

See original here:
Coronavirus Updates: The Latest Treatments and Vaccines - GovTech

Recommendation and review posted by Bethany Smith

Dataintelo offers a latest published report on Global Hematopoietic Stem Cell Transplantation (HSCT) Market industry analysis and forecast 20192025 delivering key insights and providing a competitive advantage to clients through a detailed report. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report contains XX pages which highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.

Hematopoietic Stem Cell Transplantation (HSCT) Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the Hematopoietic Stem Cell Transplantation (HSCT) global status and trend, market size, share, growth, trends analysis, segment and forecasts from 20192025.

Get FREE Exclusive PDF Sample Copy Of This Report: https://dataintelo.com/request-sample/?reportId=127246

The scope of the report extends from market scenarios to comparative pricing between major players, cost and profit of the specified market regions. The numerical data is backed up by statistical tools such as SWOT analysis, BCG matrix, SCOT analysis, and PESTLE analysis. The statistics are represented in graphical format for a clear understanding on facts and figures.

Customize Report and Inquiry for The Hematopoietic Stem Cell Transplantation (HSCT) Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=127246

The generated report is firmly based on primary research, interviews with top executives, news sources and information insiders. Secondary research techniques are implemented for better understanding and clarity for data analysis.

The Report Segments for Hematopoietic Stem Cell Transplantation (HSCT) Market Analysis & Forecast 20192025 are as:Global Hematopoietic Stem Cell Transplantation (HSCT) Market, by ProductsAllogeneicAutologous

Global Hematopoietic Stem Cell Transplantation (HSCT) Market, by ApplicationsPeripheral Blood Stem Cells Transplant (PBSCT)Bone Marrow Transplant (BMT)Cord Blood Transplant (CBT)

The Major Players Reported in the Market Include:Regen Biopharma IncChina Cord Blood CorpCBR Systems IncEscape Therapeutics IncCryo-Save AGLonza Group LtdPluristem Therapeutics IncViaCord Inc

The Global Hematopoietic Stem Cell Transplantation (HSCT) Market industry Analysis and Forecast 20192025 helps the clients with customized and syndicated reports holding a key importance for professionals entailing data and market analytics. The report also calls for market driven results deriving feasibility studies for client needs. Dataintelo ensures qualified and verifiable aspects of market data operating in the real time scenario. The analytical studies are conducted ensuring client needs with a thorough understanding of market capacities in the real time scenario.

Key Reasons to Purchase:

Ask for Discount on Hematopoietic Stem Cell Transplantation (HSCT) Market Report at: https://dataintelo.com/ask-for-discount/?reportId=127246

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Follow this link:
Hematopoietic Stem Cell Transplantation (HSCT) Market To Witness Huge Growth By 2027 | Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc,...

Recommendation and review posted by Bethany Smith

Bone marrow aspiration and trephine biopsy are usually performed on the back of the hipbone, or posterior iliac crest. An aspirate can also be obtained from the sternum (breastbone). For the sternal aspirate, the patient lies on their back, with a pillow under the shoulder to raise the chest. A trephine biopsy should never be performed on the sternum, due to the risk of injury to blood vessels, lungs or the heart.

The need to selectively isolate and concentrate selective cells, such as mononuclear cells, allogeneic cancer cells, T cells and others, is driving the market. Over 30,000 bone marrow transplants occur every year. The explosive growth of stem cells therapies represents the largest growth opportunity for bone marrow processing systems.

Get Access to sample pages:https://www.trendsmarketresearch.com/report/sample/3374

Europe and North America spearheaded the market as of 2018, by contributing over 74.0% to the overall revenue. Majority of stem cell transplants are conducted in Europe, and it is one of the major factors contributing to the lucrative share in the cell harvesting system market.

In 2018, North America dominated the research landscape as more than 54.0% of stem cell clinical trials were conducted in this region. The region also accounts for the second largest number of stem cell transplantation, which is further driving the demand for harvesting in the region.

Place a Direct Purchase Order @https://www.trendsmarketresearch.com/checkout/3374/Single

Asia Pacific is anticipated to witness lucrative growth over the forecast period, owing to rising incidence of chronic diseases and increasing demand for stem cell transplantation along with stem cell-based therapy. Japan and China are the biggest markets for harvesting systems in Asia Pacific. Emerging countries such as Mexico, South Korea, and South Africa are also expected to report lucrative growth over the forecast period. Growing investment by government bodies on stem cell-based research and increase in aging population can be attributed to the increasing demand for these therapies in these countries.

Major players operating in the global bone marrow processing systems market are ThermoGenesis (Cesca Therapeutics inc.), RegenMed Systems Inc., MK Alliance Inc., Fresenius Kabi AG, Harvest Technologies (Terumo BCT), Arthrex, Inc. and others.

Go here to read the rest:
Bone Marrow Processing Systems Market Top Participant to Focus on Regional Expansion - Murphy's Hockey Law

Recommendation and review posted by Bethany Smith

Brilliant news as Keisha announces daughter Aurora is back in remission Photo Keisha Pile-Gray

Amazing news has been announced today (November 30) nine-year-old Aurora Pile-Gray from Westbrook is in remission.

Aurora was diagnosed with stage 4 Burkitts Lymphoma after becoming poorly towards the end of April.

The rare cancer affects blood and bone marrow. Aurora has been undergoing chemotherapy and her family were looking at CAR-T cell therapy and an allogeneic transplant.

Earlier this year, after 4 gruelling cycles of intensive chemo, Aurora had been given the news that she was in remission, however this was short lived.

In October the family were told the cancer had in fact spread to Auroras bones and that the youngster was in need of a bone marrow transplant. The situation was also complicated by Auroras mixed ethnicity, making it that much more difficult to find a match.

Aurora is currently being treated by Royal Marsden Hospital and Great Ormond Street Hospital.

But in brilliant news Auroras mum Keisha has today revealed her daughter is now in remission.

Posting to facebook Keisha said: Aurora is officially back in remission!!

Her bone marrow assessments show no cancer cells present, and no cancer cell regeneration on new cells in both the solid and liquid part of her biopsy.

We were aware about the liquid aspirate a week ago, but weve been anxiously waiting for news on the solid part up until today!

The transplant team have also sourced an 11/12 donor match which means that Aurora will have one more round of chemotherapy and will move forward with transplant in January!

We dont know much about her donor other than her stem cells will be coming from a 36 year old female, with 2 children. We arent sure if we are allowed to get in contact before two years but just know, if you read this and its you, or of you know who it could be, we owe our entire life to you and would give you the world.

Days like today make our heart burst with pride and love and just how strong she has been throughout this whole ordeal. We are forever in awe of how she has tackled this journey and we are absolutely overjoyed that things are starting to look up!

Theres still a long way to go, but shes already come this far, we are all so over the moon, and I can barely get my words out, so for now, we are celebrating that out little lion is fighting on.

Matching bone marrow donors is a much more complex process than matching blood type. It relies on matching individual tissue type, and genetic markers that are found on most cells in the body. These markers are used by the immune system as a way to distinguish what cells are supposed to be in the body, and which arent. The markers must be as closely matched as possible between host and guest, to prevent the body rejecting the new bone marrow. Everyones tissue type is inherited, so often bone marrow donations come directly from a donor with the same ethnic background.

Theres a lack of individuals from ethnic minorities on the register, and as a whole only 2% of the entire UK population is currently signed up to become a bone marrow donor despite having a 1 in 800 chance you would be a match for someone.

Keisha added: Auroras in remission but we still have to get her through transplant and theres a 90% chance it could return within a year. Were made up, but still very apprehensive.

This month Keisha and Aurora were announced as joint winners, alongside Westgates Wilfred Jenkins, after our call out for Thanet heroes of 2020.

And Keishas latest update here

Find out how to join the bone marrow register:

http://www.anthonynolan.org

http://www.dkms.org

A fundraising page has been set up to help the family in case treatment abroad is needed.

Related

Read more here:
Family 'over the moon' as nine-year-old Aurora confirmed as being back in remission - The Isle of Thanet News

Recommendation and review posted by Bethany Smith

The researchers noted a weakening of possible repair mechanisms of blood vessels in patients who showed clinically significant vasoplegia

Vasoplegia, where vaso refers to blood vessels and plegia stands for paralysis, is a condition where the patient exhibits a low blood pressure, even in the presence of normal or increased output of blood from the heart. When this occurs as a complication of cardiopulmonary bypass surgery, there is a chance that it can lead to multiple organ failure and even death. Now, a diverse group of researchers including clinicians, computational biologists and biotechnologists have come together to study how this may be predicted early on based on clinical observations, so that effective treatment may be given.

Also Read | Mumbais first robot-assisted cardiac surgery

In a pilot study involving 19 patients who underwent elective cardiac surgery, the researchers measured the circulating counts of endothelial progenitor cells and hematopoietic stem cells at different points in time starting from when the patient was being anaesthetised to until 24 hours after the surgery. They find that in a statistically significant number of people in the group that showed clinically significant vasoplegia, there was a blunting of the endothelial progenitor cell response. Also, in the group that did not show clinically significant vasoplegia, they observed that there was no such blunting.

We can say there appears to be a pattern, which is well worth exploring in a larger cohort of patients and further delineating this particular response as a biomarker in predicting a potentially devastating complication following cardiac surgeries, says Dr. Paul Ramesh Thangaraj, from the department of cardiothoracic surgery, Apollo Hospitals, Chennai, who is one of the PIs of the study. This research is published in the journal PLOS ONE.

Hematopoietic and endothelial progenitor cells play an important role in repair of damaged tissues and inner lining of the blood vessels called the endothelium, respectively. Usually, these cells reside in the bone marrow; however, in response to injury to a tissue or a blood vessel, they come out into the circulation from the bone marrow and home into the site of injury for tissue repair, says Madhulika Dixit from the Department of Biotechnology, Indian Institute of Technology Madras, in an email to The Hindu.

Prof Dixit describes using flow cytometry to measure the counts during the surgery and afterwards. The cells were identified by means of expression of specialised cell surface receptors. For this, at regular intervals the blood withdrawn from the patient was subjected to flow cytometry. We checked for time-dependent changes in circulating counts of progenitor cells during the course of cardiopulmonary bypass in patients.

Also Read | Minimally invasive cardiac surgery the best bet

One of the key challenges was to get significant patterns in this small dataset, according to Rahul Siddharthan, from The Institute of Mathematical Sciences, Chennai, who was one of the people involved in formal analysis. In this case, we have two data sets, with two-valued outcomes [non-vasoplegic or vasoplegic], and the goal is to see how other measured parameters can predict them, he says. There are very sophisticated machine-learning algorithms available these days for such tasks. In this case the most basic algorithm, logistic regression, is good enough, says Prof. Siddharthan.

As he explains, in both cases, the idea is to look at a single value (change in circulating progenitor cells at two timepoints) and in seeing its predictive power for the output. The trend is clear, that for non-vasoplegic patients, the level of circulating progenitor cells increases, while for vasoplegic patients, it stays flat or decreases. There are exceptions but the finding is statistically significant even on this small study, says Prof. Siddharthan.

With a larger study, Dr.. Paul Ramesh envisages even developing a risk score for predicting vasoplegia as a complication following surgery.

More:
Pilot study finds potential signal indicative of loss of tone in blood vessels after cardiac surgery - The Hindu

Recommendation and review posted by Bethany Smith

The elated family of a nine-year-old girl battling a rare cancer has revealed she is back in remission and a bone marrow donor has been found.

The odds had been stacked against Aurora Pile-Gray, from Westgate, who was diagnosed with stage 4 Burkitt Lymphoma in May, which affects the blood and bone marrow.

Not only did she need a bone marrow transplant, but in September her parents were told her cancer was more aggressive than ever, just two weeks after being given the all-clear.

But now, mum Keisha, who also has a baby son Oscar and two-year-old daughter Ada-Ireland, has announced the news they have all been desperately waiting for - that brave Aurora, who has undergone gruelling rounds of chemotherapy, is in remission.

A donor has also been found meaning she will have a transplant in the new year.

Writing on Facebook, Keisha said: "Her bone marrow assessments show no cancer cells present, and no cancer cell regeneration on new cells in both the solid and liquid part of her biopsy.

"We were aware about the liquid aspirate a week ago, but we've been anxiously waiting for news on the solid part up until today.

"The transplant team have also sourced an 11/12 donor match which means that Aurora will have one more round of chemotherapy and will move forward with transplant in January.

"We don't know much about her donor other than her stem cells will be coming from a 36-year-old female, with two children.

"We aren't sure if we are allowed to get in contact before two years but just know, if you read this and it's you, or if you know who it could be, we owe our entire life to you and would give you the world.

"Days like today make our heart burst with pride and love at just how strong she has been throughout this whole ordeal.

"We are forever in awe of how she has tackled this journey and we are absolutely overjoyed that things are starting to look up.

"There's still a long way to go, but she's already come this far, we are all so over the moon, and I can barely get my words out, so for now, we are celebrating that our little lion is fighting on."

The community has been rallying round to help the family raise money towards life-saving cell treatment abroad for the St Crispin's pupil.

For more on her journey see growingpainspaperplanes.wordpress.com.

Read more: All the latest news from Thanet

See the article here:
Family's joy as schoolgirl, 9, back in remission - Kent Online

Recommendation and review posted by Bethany Smith

A one-year-old boy has been diagnosed with a condition so rare only one in a million people suffer from it.

Max Gardner was diagnosed with aplastic anaemia - a condition that means the bone marrow and stem cells do not produce enough blood cells and is fatal if untreated.

He was diagnosed after his parents, Connor Gardner and Rachel Nicholson, who live in Hebburn, became alarmed by significant bruising and rashes all over his body.

The couple took him to South Tyneside District Hospital, where he was incorrectly diagnosed with immune thrombocytopenic purpura, a condition which a child will grow out of.

However, as Maxs condition worsened, he ended up at the Royal Victoria Infirmary in Newcastle, where doctors conducted tests which showed he had the much rarer aplastic anaemia.

Connor said: He looked like he was a child abuse victim; we were really worried about what people would think, as he was covered in bruises.

We took him to the RVI for further tests, and they realised that maybe the condition was worse. Initially, we thought he would be diagnosed with leukaemia, but the consultant told us that it was aplastic anaemia after a bone marrow biopsy, which was administered under anaesthetic.

They told us about the condition, and that the outcome could lead to death if Max was to catch any type of sickness bug, as his immune system was non-existent.

We got our emotions out after we got the diagnosis we had a cry but we knew that we needed to be there for Max and help him get better.

The only way to cure aplastic anaemia fully is with a bone marrow transplant, and both Connor, 29, and Rachel, 27, were tested to see if they were matches.

Fortunately, Rachel was a near-perfect match, a very rare scenario.

Connor said: Usually they would use siblings for the transplant but Max does not have any. There is about a 25% chance that me or Rachel would be a match, and then there is about a 1% chance that it would be a 9/10 match.

The condition that Max has affects one in a million people, so it is very unfortunate for Max to have had this condition, but it is lucky that his mother has been a near-perfect match.

Chemotherapy is the next stage before you have the transplant, but that can lead to wiping out fertility, so we agreed to a new trial that would give Max the best chance of being able to have children of his own when he grows up.

They take a biopsy of one of his testicles and they store it for future; it is the best chance he has of having a child when he is older if he is infertile.

The family now have to shield for two weeks, before Max and his mother head back to hospital and onto the transplant ward, where he will spend the next two months.

Fortunately, Rachel can stay with Max during this time, but Connor can only see his son at specific visiting hours and has to isolate, so that the risk of spreading any illness is at a minimum.

He said: Max starts his chemotherapy on December 10, which takes place over five days, and during that time Rachel will be getting treatment so that the hospital can help harvest her bone marrow.

Then, when she goes to give the transplant, she will be there for four hours while the machine separates the bone marrow before it is given to Max.

Then he gets a bone marrow transplant, which is very similar to a normal blood transfusion."

Connor and Rachel have set up a fundraising page to help pay for the added costs of not working and to help them support them through this tough time.

He said: We have been overwhelmed with the support that people have given us and the GoFundMe page has been a great way for people to give us time.

I have been taken back by the generosity of total strangers.

Connor stressed the importance of raising awareness for bone marrow transplants, and had his fiance not been a very rare match, they would likely have had to wait for a match on the donor register.

I think it is important to raise awareness of the Anthony Nolan page. We have been lucky enough to get a donor for Max through his mam, but there are lots of people out there who have not been so lucky and are waiting for a donor.

We have met a little girl who is eight years old and she hasnt got a match yet, so we are just hoping that people will join the donor list as it may save someones life.

You can donate to the fundraising campaign by visiting here.

Follow this link:
Family's heartache after Hebburn boy diagnosed with one in a million condition - Chronicle Live

Recommendation and review posted by Bethany Smith

By Adam Owens, WRAL anchor/reporter

A 74-year-old Raleigh man spends an average of two weeks a month traveling around the world delivering stem cells or bone marrow to patients as part of Be The Match, a volunteer-based donor program.

According to Troy "Davis" Moore, Be The Match uses a database of 135 countries to find life-saving bone marrow or stem cells for patients with leukemia and other blood diseases. The stem cells are delivered from donors to patients around the world by volunteers like Moore.

Moore said, when he retired 17 years ago, gardening and working around the house just wasn't enough. His friend, who was already a volunteer courier with Be The Match, told him about the opportunity.

To date, Moore has logged more than 5,000 hours as a volunteer courier. He has traveled as far as London, Barcelona, Croatia, Portugal, Singapore and Taiwan.

On Thanksgiving week, Moore will travel to South America to pick up blood stem cells and deliver them to a patient in the United States. He had to get a rapid COVID-19 test before his trip.

"It's been a lot more challenging during COVID-19 because the rules have changed so much in these countries," said Moore, explaining he recently ran into some trouble in Croatia when he hadn't had a coronavirus test in 72 hours.

Moore said, although he doesn't get to meet the families he helps due to confidentiality, the job is incredibly special. In an interview with WRAL's Adam Owens, Moore described a trip he made on Christmas Day, 10 years ago, to deliver bone marrow from the United Kingdom to a hospital in Columbus, Ohio.

Moore said a nurse was walking him through the hospital hallways when she tapped on his shoulder and pointed to a patient room. Inside, he saw the parents of a child waiting for a transplant. "I have children and I could only imagine," Moore said. "They were just pacing down the room, waiting for it."

Moore said he plans to keep traveling until he can't anymore. Volunteering works well for him, he said, especially now that his children are grown.

Some people might get caught up in the adventure of travel, Moore said, but he's usually only in another country for one day.

"At some point, you realize that's not what it's all about," he said. "It's about getting [a cure] to someone."

See the rest here:
Raleigh man delivers stem cells to patients around the world - WRAL.com

Recommendation and review posted by Bethany Smith

The U.S. Food and Drug Administration (FDA) has approved naxitamab* (naxitamab-gqgk; Danyelza; Y-mAbs Therapeutics), a humanized form of the mouse antibody 3F8, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response (PR), minor response (mR), or stable disease (SD) to prior therapy.[1]

A rare diseaseNeuroblastoma is a heterogeneous pediatric neoplasm that arises in the sympathetic nervous system. The disease is the most common extra-cranial solid tumor in infants and children, representing between 8%-10% of all childhood tumors. Overall, neuroblastoma accounts for approximately 15% of all cancer-related deaths in children. [1]

The clinical behavior of neuroblastoma is highly variable, with some tumors being easily treatable, resulting in near-uniform survival. The majority of tumors are, however, very aggressive, with a high risk of death. [2] Age, stage, and amplification of the MYCN oncogene are the most validated prognostic markers.[2]

The incidence of neuroblastoma is 10.2 cases per million children under 15 years of age. [3] In the United States, nearly 700 new cases are reported each year. While 90% of cases are diagnosed before the age of 5, approximately 30% of patients are diagnosed within the first year. The median age of diagnosis is 22 months. [4]

Neuroblastoma develops in very early forms of nerve cells that are usually found in a developing baby, which explains why children as young as newborns can develop this cancer.

The disease rarely presents in adolescence and adulthood, but outcomes are much poorer in this age group. There does not appear to be an increased prevalence among races, but there is a slight predilection for males (1.2:1).[4]

Neuroblastoma develops in a part of the peripheral nervous system called the sympathetic nervous system. Since some of the sympathetic nervous system cells are concentrated in the adrenal glands, which sit above the kidneys, neuroblastoma often starts growing there. Tumors typically begin in the belly, neck, chest, pelvis, or adrenal glands and can spread to other parts of the body, including the bones.

All patients are staged based on the International Neuroblastoma Staging System Committee (INSS) system, ranging from stage 1 through stage 4S. Based on this staging system, patients with stage 4 disease diagnosed after one year of age are classified in the high-risk category, where the neuroblastoma tumor cells have already metastasized to other sites in the body, such as the bone or bone marrow.

Essentially all patients who have tumors with many copies, or amplification, of the MYCN oncogene also have high-risk disease, even if they do not have evidence of the tumor having spread.

Although children with a family history of neuroblastoma may have a higher risk for developing this disease, this factor accounts for only 1-2 % of all cases of neuroblastoma. The vast majority of children who develop the tumor, do not have a family history of the same.

Mechanism of actionIn simple terms, naxitamab, conceived and developed by physician-scientist Nai-Kong Cheung, M.D., Ph.D., a medical oncologist at Memorial Sloan Kettering ** who heads the organizations neuroblastoma program, detects neuroblastoma cells that have survived chemo- or radiation therapy by attaching to GD2, a ganglioside that is ubiquitously expressed in the plasma membrane of neuroblastoma and is shed into the circulation, after which the patients own immune system, especially white blood cells, can destroy the malignant neuroblastoma cells. [5]

In the late 1980s, investigators at Memorial Sloan Kettering started using 3F8 in combination with surgery and chemotherapy to treat patients diagnosed with neuroblastoma. The investigational treatment significantly improved cure rates for pediatric patients with high-risk disease.

Later, in 2007, Cheung and colleagues began developing a humanized form of 3F8 called Hu3F8. In August 2011 the researchers started a phase I study of Hu3F8 (NCT01419834). The study was designed to investigate the best and safest dose to give to patients.

Accelerated approval The new indication of naxitamab + GM-CSF is approved under accelerated approval regulation based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial.

Naxitamab is a humanized, monoclonal antibody that targets the ganglioside GD2, which is highly expressed in various neuroectoderm-derived tumors and sarcomas. The drug is administered to patients three times per week in an outpatient setting and the treatment is repeated every four weeks. The product has received Priority Review, Orphan Drug, Breakthrough Therapy, and Rare Pediatric Disease designations from the FDA.

Much needed treatmentOver the last decades, the development of novel treatments for pediatric cancers has been successful. For example, the five-year survival rates for children diagnosed with cancer in the late 1980s approaches 70%. For some types of localized embryonal tumors, including retinoblastoma and Wilms tumor, the cure rates approach or exceed 90%.

However, for every two children who survive today, one child still succumbs to their disease. And for some childhood cancers, such as neuroblastoma and certain types of brain cancer, the prognosis remains poor. Hence, despite the observed successes, there remained a major unmet medical need remains patients diagnosed with neuroblastoma. The development and subsequent approval of naxitamab may be one much-needed treatment options for these patients. [6]

[The approval represents a major milestone] for children living with refractory/relapsed high-risk neuroblastoma, noted Thomas Gad, founder, Chairman, and President of Y-mAbs Therapeutics, whose own daughters neuroblastoma was successfully treated with 3F8 at Memorial Sloan Kettering more than a decade ago.

In 2015, Memorial Sloan Kettering licensed Hu3F8 to Y-mAbs Therapeutics tpo expand the clinical trial and development program and manufacturing of naxitamab.

Its very exciting to see this treatment go from being an experimental therapy used at my daughters bedside to now being FDA approved, Gad added.

We believe that naxitamab in combination with GM-CSF is a much-needed treatment for patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow who have historically not had approved treatments available. This approval of Y-mAbs first BLA represents a key step in working towards our mission of becoming a world leader in developing better and safer antibody-based oncology products addressing unmet pediatric and adult medical needs, said Claus Moller, Y-mAbs Therapeutics Chief Executive Officer.

Clinical trialsThe FDA approval of naxitamab is supported by clinical evidence from two pivotal studies in patients with high-risk neuroblastoma with refractory or relapsed disease.

In these clinical studies, naxitamab appears to be well tolerated with few discontinuations of treatment. The observed treatment-related adverse events were clinically manageable.

The efficacy of naxitamab in combination with GM-CSF was evaluated in two open-label, single-arm trials in patients with high-risk neuroblastoma with refractory or relapsed disease in the bone or bone marrow.

Both trials included patients with relapsed or refractory neuroblastoma in the bone marrow or bone. Participating patients received a 3 mg/kg of naxitamab intravenously on days one, three, and five of each four-week cycle, in addition to GM-CSF subcutaneously, or under the skin, at varying doses throughout the cycle. Patients were allowed to receive preplanned radiation in specific areas based on which trial they were enrolled in.

Efficacy outcomes included overall response rate (ORR) according to the revised International Neuroblastoma Response Criteria (INRC), as determined by independent pathology and imaging review and confirmed by at least one subsequent assessment. An additional efficacy outcome measure was the duration of response (DOR).

Study 201In the first study (Study 201; NCT03363373), a multicenter open-label, single-arm trial. researchers evaluated the combination of naxitamab in combination with GM-CSF in a subpopulation of patients who had refractory or relapsed high-risk neuroblastoma in the bone or bone marrow and demonstrated a partial response, minor response, or stable disease to prior therapy. Patients with progressive disease were excluded.

Of the 22 patients included in the efficacy analysis, 64% had refractory disease and 36% had relapsed disease. The median age was 5 years (range 3 to 10 years), 59% were male; 45% were White, 50% were Asian and 5% were Black.

MYCN amplification was present in 14% of patients and 86% of patients were International Neuroblastoma Staging System (INSS) stage 4 at the time of diagnosis. Disease sites included 59% in the bone only, 9% in bone marrow only, and 32% in both. Prior therapies included surgery (91%), chemotherapy (95%), radiation (36%), autologous stem cell transplant (ASCT) (18%), and anti-GD2 antibody treatment (18%).

Study 12-230The second study (Study 12-230; NCT01757626), a single-center, open-label, single-arm clinical trial, included a subpopulation of patients who had relapsed or refractory high-risk neuroblastoma in bone or bone marrow and demonstrated a partial response, minor response, or stable disease to prior therapy. In this study patients with progressive disease were excluded.

Participating patients received at least one systemic therapy to treat disease outside of the bone or bone marrow prior to enrollment. They were required to have received at least one dose of naxitamab at a dose of 3 mg/kg or greater per infusion and have evaluable disease at baseline according to independent review per the revised INRC. Radiation to non-target bony lesions and soft tissue lesions was permitted at the investigators discretion (assessment of response excluded sites that received radiation).

Of the 38 patients included in the efficacy analysis, 55% had relapsed neuroblastoma and 45% had refractory disease; 50% were male, the median age was 5 years (range 2 to 23 years), 74% were White, 8% Asian and 5% were Black, 5% Native American/American Indian/Alaska Native, 3% other races and 5% was not available. MYCN-amplification was present in 16% of patients and most patients were International Neuroblastoma Staging System (INSS) stage 4 (95%).

Fifty percent (50%) of patients had disease involvement in the bone only, 11% only in bone marrow, and 39% in both. Prior therapies included surgery (100%), chemotherapy (100%), radiation (47%), autologous stem cell transplant (ASCT) (42%), and anti-GD2 antibody treatment (58%)

Adverse eventsThe most common adverse reactions (incidence 25% in either trial) in patients receiving naxitamab were infusion-related reactions, pain, tachycardia, vomiting, cough, nausea, diarrhea, decreased appetite, hypertension, fatigue, erythema multiforme, peripheral neuropathy, urticaria, pyrexia, headache, injection site reaction, edema, anxiety, localized edema, and irritability.

The most common Grade 3 or 4 laboratory abnormalities (5% in either trial) were decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased platelet count, decreased potassium, increased alanine aminotransferase, decreased glucose, decreased calcium, decreased albumin, decreased sodium, and decreased phosphate.

Boxed warningThe prescribing information for naxitamab contains a Boxed Warning which states that the drug can cause serious infusion-related reactions and neurotoxicity, including severe neuropathic pain, transverse myelitis, and reversible posterior leukoencephalopathy syndrome (RPLS). Hence, to mitigate these risks, patients should receive premedication prior to each naxitamab infusion and be closely monitored during and for at least two hours following completion of each infusion.

Note* Also known as humanized 3F8 or Hu3F8,** Researchers at Memorial Sloan Kettering Cancer Center (MSK) developed naxitamab, which is exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests related to the compound and Y-mAbs.

Clinical trialsHumanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors NCT01419834Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors NCT01662804Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma NCT02650648Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers NCT03860207Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma NCT01757626Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow NCT03363373

Highlights of prescription informationNaxitamab (naxitamab-gqgk; Danyelza; Y-mAbs Therapeutics) [Prescribing Information]

Reference[1] Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010 Feb;24(1):65-86. doi: 10.1016/j.hoc.2009.11.011. PMID: 20113896.[2] Modak S, Cheung NK. Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treat Rev. 2010 Jun;36(4):307-17. doi: 10.1016/j.ctrv.2010.02.006. Epub 2010 Mar 12. PMID: 20227189.[3] Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010 Jun 10;362(23):2202-11. doi: 10.1056/NEJMra0804577. PMID: 20558371; PMCID: PMC3306838.[4] Esiashvili N, Anderson C, Katzenstein HM. Neuroblastoma. Curr Probl Cancer. 2009 Nov-Dec;33(6):333-60. doi: 10.1016/j.currproblcancer.2009.12.001. PMID: 20172369.[5] Balis FM, Busch CM, Desai AV, Hibbitts E, Naranjo A, Bagatell R, Irwin M, Fox E. The ganglioside GD2 as a circulating tumor biomarker for neuroblastoma. Pediatr Blood Cancer. 2020 Jan;67(1):e28031. doi: 10.1002/pbc.28031. Epub 2019 Oct 14. PMID: 31612589.[6] Balis FM. The Challenge of Developing New Therapies for Childhood Cancers. Oncologist. 1997;2(1):I-II. PMID: 10388032.

Featured image: A close up of a newborn babys foot in the neonatal unit in a hospital. Photo courtesy: 2016 2020 Fotolia/Adobe. Used with permission

Follow this link:
US FDA Approves Naxitamab for the Treatment of Neuroblastoma - OncoZine

Recommendation and review posted by Bethany Smith